[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2017163264A1 - Blocking toll-like receptor 9 signaling with small molecule antagonist - Google Patents

Blocking toll-like receptor 9 signaling with small molecule antagonist Download PDF

Info

Publication number
WO2017163264A1
WO2017163264A1 PCT/IN2017/050103 IN2017050103W WO2017163264A1 WO 2017163264 A1 WO2017163264 A1 WO 2017163264A1 IN 2017050103 W IN2017050103 W IN 2017050103W WO 2017163264 A1 WO2017163264 A1 WO 2017163264A1
Authority
WO
WIPO (PCT)
Prior art keywords
tbp
methoxy
quinazolin
compound
pyrrolidin
Prior art date
Application number
PCT/IN2017/050103
Other languages
French (fr)
Other versions
WO2017163264A4 (en
Inventor
Arindam Talukdar
Dipyaman Ganguly
Barnali PAUL
Ayan MUKHERJEE
Shounak ROY
Swarnali ROY
Amrit Raj GHOSH
Roopkatha BHATTACHARYA
Oindrila RAHAMAN
Biswajit KUNDU
Original Assignee
Council Of Scientific & Industrial Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Of Scientific & Industrial Research filed Critical Council Of Scientific & Industrial Research
Priority to AU2017238758A priority Critical patent/AU2017238758B2/en
Priority to CA3018537A priority patent/CA3018537A1/en
Priority to US16/086,926 priority patent/US10662177B2/en
Priority to EP17725784.7A priority patent/EP3433249B1/en
Priority to DK17725784.7T priority patent/DK3433249T3/en
Publication of WO2017163264A1 publication Critical patent/WO2017163264A1/en
Publication of WO2017163264A4 publication Critical patent/WO2017163264A4/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Definitions

  • the invention relates small molecule antagonist
  • the innate immunity is comprised of several types of cells including dendritic cells (DC’s), macrophages and monocytes, polymorphonuclearcells, natural killer (NK) cells, innate lymphoid cells and natural killer T cells (NKT cells) which detects various pathogens as well asaberrant hostcells with potential for danger to tissue integrity through specialized receptors like toll-like receptors.
  • DC dendritic cells
  • NK natural killer
  • NKT cells natural killer T cells
  • Toll-like receptors TLRs
  • TLRs are a family of germline-encoded cell surface pattern recognition molecules containing an pathogen binding ectodomain (ECD) with 19-25 leucine-rich repeats (LRRs), a transmembrane domain and a characteristic cytoplasmic domain called the TIR (Toll/IL ⁇ 1 receptor) domain.
  • TIR domain is responsible for downstream signalling, whereas LRRs containing 24–29 amino acids are responsible for ligand recognition and binding.
  • TLRs get triggered in response to bacterial and fungal infections (Medzhitov, R;Nat. Rev. Immunol. 1, 135-145, 2001) followed by induction of downstream signalling, leading to expression of inflammatory genes like those of the nuclear factor- ⁇ B (NF- ⁇ B) family of transcription factors and antimicrobial peptides.
  • NF- ⁇ B nuclear factor- ⁇ B
  • miceTLRs There are 11 human and 12 miceTLRs have been identified which recognize different molecular patterns on the pathogens.
  • TLRs Major group of the TLRs are expressed on the cell surface.
  • the leucine-rich repeats in the ectodomains of these molecules bind to unique molecular entities on pathogens (PAMPs), which detect and initiate responses to invading microorganisms (Akira, S; et al. Annu Rev Immunol. 21, 335-76, 2003).
  • PAMPs pathogens
  • Another group of TLRs endosomal TLRs
  • TLRs endosomal TLRs
  • This group comprises of TLR3 (Alexopoulou, L; et al.
  • TLR7 Hemmi, H; et al. Nature, 408(6813), 740-5, 2001; Lund, J. M; et al. ProcNatlAcadSci U S A. 101(15), 5598-603, 2004
  • TLR8 Heil, F; et al. Science, 303(5663), 1526-9, 2004
  • TLR9 Hemmi, H; et al. Nature, 408(6813), 740-5, 2001.
  • the endosomal TLRs are specialized for detecting microbial nucleic acids after microbes get phagocytosed and reach the endosomal compartments.
  • the downstream signalling goes through recruitment of intracellular adaptor molecules such as Myd88 (or the myeloid differentiation primary-response gene 88), TIRAP (or the TIR-domain containing adaptor protein), TRIF (or the TIRAP inducing IFN-beta) and TRAM (or the TRIF-related adaptor molecule).
  • TLR-adaptor molecule interactions in turn recruit other proteins to the signalling complex, which initiates multiple downstream signalling pathways, leading to activation of NFkB or mitogen- activated protein kinases (MAPKs) or recruitment of the IFN regulatory factors (IRFs).
  • TLR3, 7, 8, 9 The intracellular localization of the nucleic acid-recognizing TLRs (TLR3, 7, 8, 9) is one of the mechanisms that prevent their spontaneous activation by circulating host- derived nucleic acids (Barton, G. M; et al. Nat Immunol. 7(1):49-56, 2006), however under certain pathological conditions the endogenous nucleic acids can overcome this regulation.
  • TLR9, 7 and 8 activation driven by self nucleic acid and LL37 complexes may also play an important pathogenic role in Psoriasis (Lande, R; et al. Nature, 449(7162), 564-9, 2007; Ganguly, D. et al. J Exp Med.206(9), 1983-94, 2009).
  • These associated proteins may protect thebound nucleic acid from degradation and/or facilitate their entry into the cell, as is the case for Fc receptor-mediated uptake of antibody-nucleic acid complexes (Leadbetter, F. A; et al. Nature, 416(6881), 603-7, 2002;Ganguly, D. et al. J Exp Med.
  • the nucleic acid cargo can then stimulate the intracellular TLRs, priming the immune system for a cascade of inflammation inciting cytotoxic and/or humoral response.
  • this cycle of innate immune recognition, generation of autoreactive antibodies, and consequent immune complex formation is believed to play critical role in the pathogenesis of SLE and possibly Sjogren’s syndrome (Marshak-Rothstein, A; Nat Rev Immunol. 6(11), 823-35, 2006; Lande, R; et al. Nature, 449(7162), 564-9, 2011; Ganguly, D. et al. Nat Rev Immunol.
  • TLR7 and TLR9-competitive antagonist oligonucleotides Barrat, F. J; et al. Eur J Immunol.37(12), 3582-6, 2007; Christensen, S. R; et al. J Exp Med. 202(2), 321-31, 2005.
  • TLR-mediated pathological responses to nucleic acids have also been shown to contribute to other pathologies like psoriasis (Lande R et al, Nature, 2007; Ganguly D et al, J Exp Med, 2009), ischemic liver injury (Bamboat, Z. M; et al.
  • the main object of the present invention is to provide compounds of general formula I.
  • Another object of the present invention is to provide a screening method involving human peripheral blood mononuclear cells to screen compounds of general formula I against TLR9.
  • Yet anotherobjectiveof the present invention is to provide a method for testing TLR9 antagonism of compounds of general formula I, in primary human plasmacytoid dendritic cells (pDCs) purified from human peripheral blood mononuclear cells.
  • pDCs primary human plasmacytoid dendritic cells
  • Yet another object of the present invention is to provide composition and methods of compounds of general formula I that can be used in a number of clinical applications, including as pharmaceutical agents and methods for treating conditions involving untoward immune hyperactivity.
  • Yet another object of the present invention is to provide composition and methods of compounds of general formula I without considerable cytotoxicity in HepG2 (a hepatic epithelial cell line) and SW480 (an intestinal mucosal epithelial cell line) cells at concentrations below 100 ⁇ M.
  • X is independently selected from groups referred to as follows:
  • R 1 is independently selected from groups referred to as follows:
  • R 5 and R 6 are independently hydrogen or substitutedor unsubstitutedalkyl or R 5 and R 6 is joined to form substituted or unsubstitutedheterocycle.
  • R 2 is independently selected from groups referred to as follows:
  • R 3 is independently selected from groups referred to as hydrogen, -OH and –OCH 3 groups.
  • the gagtural formulae of general formula 1 is consisting the representative compounds :
  • step b reacting compound 7 obtained in step a) with amine to obtain compound of formula 8 or 14 or 32;
  • step c reacting compound 8 or 14 or 32 of step b) either with with hydrogen in presence of Pd/C to obtain compound of 9 or 15 or reacting with TFA to obtain 29a or 29b or 33 ; d. reacting compound 9 or 15 of step c) either with 1-chloro-3-bromopropane or bromocyclopentane to obtain compound 10 or 26 or 16 ;
  • step d reacting compound 10 or 16 of step d) with amine to compound 11 or 17; f. reacting compound 11 or 17 of step e) or compound 26 of step d) or compound 14 of step b) with TFA to obtain 12 or 18 or 27;
  • step f) further comprises, reacting compound 27 of step f) with alkyl halide or acid chloride to obtain compound of formula 1 or compound 31;
  • the compound 31 further reacted with hydrogen in presence of Pd/C to obtain compound of formula 1.
  • the process further comprising(i) reacting compound 6 with N- cyclopentylpiperazine or N-methyl piperazine followed by dimethyl amine to obtain an interemediate
  • the amine used in step b) r step e) is selected from the group consisting of,
  • the sulphonyl chloride is selected from the group consisting of,
  • the alkyl or aryl carboxylic acid or acid chloride is selected from the group consisting of,
  • the alkyl halide is selected from the group consisting of,
  • the alkyl o aryl aldehyde is selected from the group consisting of,
  • a general screening method is provided involving human peripheral blood mononuclear cells to screen compounds of general formula I against all TLRs.
  • a method is provided for testing TLR9 antagonism of compounds of general formula I, in primary human plasmacytoid dendritic cells (pDCs) purified from human peripheral blood mononuclear cells.
  • pDCs primary human plasmacytoid dendritic cells
  • a reporter assay method is provided involving a cell line expressing TLR9 to screen compounds of general formula I for TLR9 antagonism.
  • said compoundswith formula (I) described by the presentinvention affect immune stimulation via interaction with aTLR9.
  • aTLR9 it is believed that many of the small molecules described by the presentinvention inhibit immune stimulation via TLR9 antagonism.
  • the methods of theinvention are useful whenever it is desirable to alter TLR9mediated signalling in response to a suitable TLR ligand orTLR signalling agonist.
  • the said compounds with formula (I) can be useful to inhibit an immune stimulatory nucleic acid associated response in a subject.
  • the said compounds with formula (I) shows TLR9 antagonistic activity that can modulate autoreactive inflammation in different autoimmune diseases since aberrant TLR9 activation is implicated in such diseases.
  • the said compounds with formula (I) can be used in a number of clinical applications, including as pharmaceutical agents and methods for treating conditions involving unwanted immune activity due to TLR9 activation.
  • the said compounds with formula (I) are without considerable cytotoxicity in HepG2 (a hepatic epithelial cell line) and SW480 (an intestinal mucosal epithelial cell line) cells at concentrations below 100 ⁇ M.
  • the said compounds with formula (I) can be useful in the treatment of different clinical context of autoreactive inflammation, inflammation, allergy,asthma, graft rejection, and GvHD where aberrant TLR9 activation is present.
  • the small molecules with formula (I) is believed to affect TLRs directly and thus affect TLR-bearing cells, such as antigen-presenting cells (APCs), such agents can be used in conjunction with additional agents which affect non-APC immune cells, such as T lymphocytes (T cells).
  • APCs antigen-presenting cells
  • T cells T lymphocytes
  • a method of affecting TLR mediated signalling in response to a TLR ligand involves detecting TLR9 antagonism of effective amount of a compound of Formula (I) using a reporter cell line that reports nuclear factor kappa B expression downstream of TLR9 signalling.
  • Fig.1 -Structural evolution of the quinazoline scaffold (FORMULA I) small molecules along with respective TLR9-antagonistic activity.
  • the figure denotes percent interferon alpha production in response to TLR9-agonist ODN2216 from human peripheral blood mononuclear cells in the presence of different doses of the antagonist molecules (0, 0.1, 1, 5, 10 ⁇ M).
  • Each row represents a single molecule with increasing antagonist concentrations from left to right as shown in the figure.
  • TLR9-antagonist activity of one representative molecule belonging to each structural subset is indicated.
  • Fig.2 TLR9 inhibition in pDCs by selected compounds with formula (I).
  • the graphs denote dose-dependent reduction in IFN- ⁇ production in response to TLR9- agonist ODN2216 from human plasmacytoid dendritic cells (pDC) in the presence of different doses of the antagonist molecules. Each data is derived from two donors. Average values are reported.
  • Fig.3 TLR9 inhibition inHEK-Blue-hTLR9 reporter cell line by selected compounds with formula (I).
  • the graphs denote dose-dependent inhibition of TLR9 activation in a HEK-Blue-hTLR9 reporter cell line in the presence of different doses of the antagonist molecules, which is represented in terms of decrease in SEAP activity. Data shown are mean of triplicate wells ⁇ SD.
  • Fig.4 Cytotoxicity based on MTT assay of the identified TLR9 antagonist molecules.HepG2 and SW480 cells were cultured in presence of different concentrations (0.1, 0.5,1, 10, 20 and 100 ⁇ M) of different candidate small molecule antagonists for 24 hrs. At 24 hrs MTT assay was performed as described in the text. Respective absorbance at 570nm is represented. Each line represents a specific small molecule as denoted in the legend.
  • Table 1 depicts overall structure of the compounds with quinazoline scaffold with formula (I) composition of the Invention
  • Table 2 depicts IC50 values of the compounds with quinazoline scaffold with formula (I) composition of the Invention.
  • type I interferons e.g. IFN-alpha
  • the synthesized compounds of general formula I was able to alter the release of type I interferons (e.g. IFN-alpha).
  • Type I interferons(IFN-alpha) production from human peripheral blood mononuclear cells in response to type A CpG oligonucleotides (CpGA) almost exclusively results from TLR9 triggering on the PDCs.
  • CpGA CpG oligonucleotides
  • the synthesized compounds of general formula I having TLR9 antagonistic activity inhibited IFN-alpha production in this screening assay were screened for toll-like receptor 9 antagonistic activities by a medium throughput biological assay based on toll-like receptor 9 activation in plasmacytoid dendritic cells (pDC) which were isolated from PBMCs of healthy donors.
  • the synthesized compounds of general formula I were screened for toll-like receptor 9 antagonism using a HEK-Blue- hTLR9 Secreted Alkaline Phosphatase (SEAP) reporter assay.
  • SEAP Secreted Alkaline Phosphatase
  • the synthesized compounds of general formula I werescreened for cytotoxicity.
  • MTT assay is a colorimetric assay for assessing cell viability.
  • HepG2 a hepatic epithelial cell line
  • SW480 an intestinal mucosal epithelial cell line
  • the synthesized compounds of general formula I did not show any considerable cytotoxicity at concentrations below 100uM on this assay ( Figure 4).
  • 4-(Benzyloxy)-3-methoxybenzonitrile (2) 4-hydroxy-3-methoxybenzonitrile (10.0 g, 67.11 mmol) and potassium carbonate (19 g, 134 mmol) were taken in DryDMF (20 mL) at 0 ⁇ C. And then benzyl bromide (9.0 mL, 80.5 mmol) was added to the reaction mixture very slowly. The reaction mixture was stirred 12 h at room temperature, and brine solution (100 mL) was added. The resulting precipitate was collected, washed with water and dried to provide 4-benzyloxy-3-methoxybenzonitrileas a white solid (13.9 g, 89% yield).
  • reaction mixture was extracted with ethyl acetate and washed with 50 mL of water followed by brine wash, dried with sodium sulphate and concentrated.
  • the residue was purified by silica gel flash column chromatography, eluting with 60% ethyl acetate in hexane, to give compound 10 (169 mg, 72% yield) as a colourless gummy solid.
  • TLR9 quinazoline scaffolds for toll-like receptor 9 (TLR9) antagonisms
  • TLR9 has significant expression in plasmacytoid dendritic cells (PDCs) and B lymphocytes.
  • PDCs plasmacytoid dendritic cells
  • B lymphocytes plasmacytoid dendritic cells
  • Placytoid dendritic cells are capable of producing type I interferons (e.g. IFN-alpha) in response to TLR9 ligands.
  • Type A and type B unmethylated cytosine-guanine rich DNA oligonucleotides are the bona fide ligands for TLR9.
  • CpG oligonucleotides unmethylated cytosine-guanine rich DNA oligonucleotides
  • pDC plasmacytoid dendritic cells
  • the synthesized small molecules based on quinazoline scaffolds were screened for TLR9 antagonism using a HEK-Blue-hTLR9 Secreted Alkaline Phosphatase (SEAP) reporter assay.
  • SEAP HEK-Blue-hTLR9 Secreted Alkaline Phosphatase
  • Reporter HEK cell lines expressing human TLR9 along with a NF- ⁇ B promoter driven secreted embryonic alkaline phosphatase (SEAP) reporter gene were used. 70,000 cells per well were incubated overnight at 37 0 C and 5% CO 2 in a 96 well plate in complete DMEM medium supplemented with 100 ⁇ g/ml Normocin.
  • the TLR9 agonist CpGB was added to the wells at a concentration of 1 ⁇ M in presence of escalating doses of the synthesized small molecules and incubated at 37 0 C and 5% CO 2 for 24 hours. After incubation of the HEK cells, supernatants were collected and 20 ⁇ l of supernatant was added to wells containing 200 ⁇ l of Quanti-Blue Detection media. After 2 hours of further incubation, OD values were taken at 620nm in a spectrophotometer. Molecules having TLR9 antagonistic activity inhibited TLR9- mediated NF-kB activation in a dose-dependent manner (Figure 3).
  • MTT assay is a colorimetric assay for assessing cell viability. It is widely used for screening drugs and testing their cytotoxicity. NAD(P)H-dependent cellular oxidoreductase enzymes may, under defined conditions, reflect the number of viable cells present. These enzymes are capable of reducing the tetrazolium dye MTT 3-(4, 5dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide to its insoluble formazan, which has a purple colour. Viable cells with active metabolism convert MTT into a purple coloredformazan product with an absorbance maximum near 570 nm. When cells die, they lose the ability to convert MTT into formazan, thus colour formation serves as a useful and convenient marker of only the viable cells. The exact cellular mechanism of MTT reduction into formazan is not well understood, but likely involves reaction with NADH or similar reducing molecules that transfer electrons to MTT.
  • HepG2 a hepatic epithelial cell line
  • SW480 an intestinal mucosal epithelial cell line
  • the invention provides small molecules with general formula (I) which can effect immune stimulation via TLR9 antagonism.
  • the invention provides small molecules with general formula (I) which can inhibit immune stimulation via TLR9 antagonism.
  • the invention provides a medium throughput biological assays results involving human peripheral blood mononuclear cells, isolated human primary pDCs and reporter assay using transfected TLR9 cells to screen compounds with formula (I). All the three assays system was standardized and the results from all three assay systems can be correlated.
  • This invention provides compounds with formula (I) which can be used in a number of clinical contexts of autoreactive inflammation, including as pharmaceutical agents and methods for treating conditions involving unwanted immune activity in response to a suitable TLR ligand or TLR signalling agonist.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to small molecule4-(piperazin-1-yl)quinazolin-2-amino compounds with formula (I) useful for inhibiting signalling by certain toll-like receptors (TLRs), especially TLR9. Toll-like receptors (TLRs) are members of the larger family of evolutionarily conserved pattern recognition receptors which are critical first line of defence for self-nonself discrimination by the host immune response. Aberrant TLR9 activation is implicated in autoreactive inflammation in different autoimmune diseases. The invention depicts compounds with formula (I), composition and methods can be used in a number of clinical applications, including as pharmaceutical agents and methods for treating conditions involving unwanted immune activity due to TLR9 activation.

Description

BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH SMALL
MOLECULE ANTAGONIST FIELD OF INVENTION
The invention relates small molecule antagonist
of compounds with formula (I) in free form or in acceptable salt form useful for altering immune function by blocking toll-like receptor 9 signalling.
Figure imgf000003_0001
BACKGROUND OF THE INVENTION
The innate immunity is comprised of several types of cells including dendritic cells (DC’s), macrophages and monocytes, polymorphonuclearcells, natural killer (NK) cells, innate lymphoid cells and natural killer T cells (NKT cells) which detects various pathogens as well asaberrant hostcells with potential for danger to tissue integrity through specialized receptors like toll-like receptors. Toll-like receptors (TLRs) are a family of germline-encoded cell surface pattern recognition molecules containing an pathogen binding ectodomain (ECD) with 19-25 leucine-rich repeats (LRRs), a transmembrane domain and a characteristic cytoplasmic domain called the TIR (Toll/IL ‑1 receptor) domain. TIR domain is responsible for downstream signalling, whereas LRRs containing 24–29 amino acids are responsible for ligand recognition and binding. TLRs get triggered in response to bacterial and fungal infections (Medzhitov, R;Nat. Rev. Immunol. 1, 135-145, 2001) followed by induction of downstream signalling, leading to expression of inflammatory genes like those of the nuclear factor-κB (NF- κB) family of transcription factors and antimicrobial peptides. There are 11 human and 12 miceTLRs have been identified which recognize different molecular patterns on the pathogens.
Major group of the TLRs are expressed on the cell surface. The leucine-rich repeats in the ectodomains of these molecules bind to unique molecular entities on pathogens (PAMPs), which detect and initiate responses to invading microorganisms (Akira, S; et al. Annu Rev Immunol. 21, 335-76, 2003). Another group of TLRs (endosomal TLRs) are located inside the cell within the endosomal-lysosomal compartments, instead of being expressed on the cell surface (Akira, S; et al. Annu Rev Immunol. 21, 335-76, 2003). This group comprises of TLR3 (Alexopoulou, L; et al. Nature, 413(6857), 732-8, 2001), TLR7 (Hemmi, H; et al. Nature, 408(6813), 740-5, 2001; Lund, J. M; et al. ProcNatlAcadSci U S A. 101(15), 5598-603, 2004), TLR8 (Heil, F; et al. Science, 303(5663), 1526-9, 2004) and TLR9 (Hemmi, H; et al. Nature, 408(6813), 740-5, 2001). The endosomal TLRs are specialized for detecting microbial nucleic acids after microbes get phagocytosed and reach the endosomal compartments.
The downstream signalling goes through recruitment of intracellular adaptor molecules such as Myd88 (or the myeloid differentiation primary-response gene 88), TIRAP (or the TIR-domain containing adaptor protein), TRIF (or the TIRAP inducing IFN-beta) and TRAM (or the TRIF-related adaptor molecule). TLR-adaptor molecule interactions in turn recruit other proteins to the signalling complex, which initiates multiple downstream signalling pathways, leading to activation of NFkB or mitogen- activated protein kinases (MAPKs) or recruitment of the IFN regulatory factors (IRFs). These different pathways in turn result in the transcription of genes encoding different cytokines, chemokines, co-stimulatory molecules or other proteins, thereby sculpting the ensuing immune response (Akira, S; et al. Annu Rev Immunol.21, 335-76, 2003). The intracellular localization of the nucleic acid-recognizing TLRs (TLR3, 7, 8, 9) is one of the mechanisms that prevent their spontaneous activation by circulating host- derived nucleic acids (Barton, G. M; et al. Nat Immunol. 7(1):49-56, 2006), however under certain pathological conditions the endogenous nucleic acids can overcome this regulation. It has been previously shown by us and others that the circulating immune complexes found in sera of patients suffering from systemic lupus erythematosus (SLE) typically contain nucleic acids associated with various proteins such as antibodies, the chromatin-associated protein HMGB1, the antimicrobial peptide LL37, ribonuclear proteins and others (Lande, R; et al. Nature, 449(7162), 564-9, 2011; Ganguly, D. et al. Nat Rev Immunol. 13(8), 566-77, 2013). Our previous studies have also shown that TLR9, 7 and 8 activation driven by self nucleic acid and LL37 complexes may also play an important pathogenic role in Psoriasis (Lande, R; et al. Nature, 449(7162), 564-9, 2007; Ganguly, D. et al. J Exp Med.206(9), 1983-94, 2009). These associated proteins may protect thebound nucleic acid from degradation and/or facilitate their entry into the cell, as is the case for Fc receptor-mediated uptake of antibody-nucleic acid complexes (Leadbetter, F. A; et al. Nature, 416(6881), 603-7, 2002;Ganguly, D. et al. J Exp Med. 206(9), 1983-94, 2009). Once inside the endolysosomal compartments, the nucleic acid cargo can then stimulate the intracellular TLRs, priming the immune system for a cascade of inflammation inciting cytotoxic and/or humoral response. For example, this cycle of innate immune recognition, generation of autoreactive antibodies, and consequent immune complex formation is believed to play critical role in the pathogenesis of SLE and possibly Sjogren’s syndrome (Marshak-Rothstein, A; Nat Rev Immunol. 6(11), 823-35, 2006; Lande, R; et al. Nature, 449(7162), 564-9, 2011; Ganguly, D. et al. Nat Rev Immunol. 13(8), 566-77, 2013), a finding confirmed in animal models treated with TLR7 and TLR9-competitive antagonist oligonucleotides (Barrat, F. J; et al. Eur J Immunol.37(12), 3582-6, 2007; Christensen, S. R; et al. J Exp Med. 202(2), 321-31, 2005). TLR-mediated pathological responses to nucleic acids have also been shown to contribute to other pathologies like psoriasis (Lande R et al, Nature, 2007; Ganguly D et al, J Exp Med, 2009), ischemic liver injury (Bamboat, Z. M; et al. Hepatology, 51(2), 621-32, 2010) lung infection (Itagaki, K; et al. Shock, 36(6), 548-52, 2011), pancreatitis (Hoque, R; et al. Gastroenterology, 141(1), 358-69, 2011) and graft-versus-host disease (Calcaterra, C; et al. J Immunol. 181(9), 6132-9, 2008). Hydroxychloroquine and chloroquine are not only used as anti-malarial agents but has been commonly prescribed to treat various clinical contexts of autoreactive inflammation (autoimmune diseases) such as rheumatoid arthritis (RA) and SLE (Wallace, D. J;Lupus, 5 Suppl 1, S59-64, 1996). In literature there are several reports of small molecule analogues and derivatives of chloroquine with substituted quinoline and quinazoline scaffold which can inhibit stimulation of the immune system.US. Pat. No.6,221,882; US. Pat. No. 6,479,504; US Pat. No.7,410,975 B2; WO 2008/030455, published Mar 13, 2008; US. Pat. No. US 7,410,975 B2; PCT published application PCT/US03/17733 (WO 03/103586 A2); and PCT published application PCT/US2009/058401 (WO2010/036908). OBJECTIVES OF THE INVENTION
The main object of the present invention is to provide compounds of general formula I. Another object of the present invention is to provide a screening method involving human peripheral blood mononuclear cells to screen compounds of general formula I against TLR9.
Yet anotherobjectiveof the present invention is to provide a method for testing TLR9 antagonism of compounds of general formula I, in primary human plasmacytoid dendritic cells (pDCs) purified from human peripheral blood mononuclear cells.
Yet another objective of the present invention is to provide a method for testing TLR9 antagonism of compounds of general formula I a reporter assay method involving a cell line expressing TLR9 to screen compounds of general formula I for TLR9 antagonism. Yet another objective of the present invention is to correlate the assays results involving human peripheral blood mononuclear cells, human primary pDCs and transfected TLR9 cells. Yet another object of the present invention is to provide composition and methods of compounds of general formula I with TLR9 antagonistic activity that can modulate immune responses.
Yet another object of the present invention is to provide composition and methods of compounds of general formula I that can be used in a number of clinical applications, including as pharmaceutical agents and methods for treating conditions involving untoward immune hyperactivity.
Yet another object of the present invention is to provide composition and methods of compounds of general formula I without considerable cytotoxicity in HepG2 (a hepatic epithelial cell line) and SW480 (an intestinal mucosal epithelial cell line) cells at concentrations below 100 µM. SUMMARY OF THE INVENTION
In an embodiment of the present invention, compounds of general formula I is provided.
Figure imgf000007_0001
wherein
X is independently selected from groups referred to as follows:
Figure imgf000008_0001
wherein R1 is independently selected from groups referred to as follows:
Figure imgf000008_0002
Figure imgf000008_0003
whereinR2 is a group having structure
Where Y is optionally substituted or unsubstituted C0 to C3alkyl; R5 and R6 are independently hydrogen or substitutedor unsubstitutedalkyl or R5 and R6 is joined to form substituted or unsubstitutedheterocycle. wherein R2 is independently selected from groups referred to as follows:
Figure imgf000009_0001
wherein R3 is independently selected from groups referred to as hydrogen, -OH and –OCH3 groups.
In another embodiment the compounds of general formula 1 is represented by compounds encompassing:
4-(4-(Isopropylsulfonyl)piperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(3- (pyrrolidin-1-yl)propoxy)quinazolin-2-amine13a(TBP-2-93);
4-(4-(Dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1yl)propoxy)quinazolin-4- yl)-N,N-dimethylpiperazin-1-sulfonamide13b(TBP-2-121);
Cyclopentyl(4-(2-(dimethylamino)-6-methoxy-7-(3-(pyrrolidin- 1yl)propoxy)quinazolin-4-yl)piperazine-1yl)methanone13c(TBP-2-117);
4-(4-(Cyclopentylmethyl)piperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(3- (pyrrolidin-1yl)propoxy)quinazolin-2-amine 13d(TBP-3-79);
4-(4-(Cyclopentylpiperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(3-(pyrrolidin- 1yl)propoxy)quinazolin-2-amine 13e(TBP-3-73);
(4-(2-(Dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline- 4-yl)piperazin-1-yl)(phenyl)methanone 13f(TBP-3-75);
4-(4-Benzylpiperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-2-amine 13g(TBP-3-67); (4-(Aminomethyl)phenyl)(4-(2-(dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-4-yl)piperazin-1-yl)methanone 13h (TBP-3-113);
6-((4-(4-(2-(Dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-4-yl)piperazine-1-carbonyl)benzyl)amino)-6- oxohexanoic acid 13i (TBP-3-115);
6-((4-(4-(2-(Dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-4-yl)piperazine-1-carbonyl)benzyl)amino)-6- oxohexanoic acid 13i (TBP-3-115);
2-(4-(2-(dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin- 4-yl)piperazin-1-yl)-1-(4-fluorophenyl)ethanone13j (TBP-4-81);
t-Butyl-4-(6-methoxy-7-(3-morpholinpropoxy)-2-(pyrrolidin-1-yl)quinazoline- 4-yl)piperazine-1-carboxylate 17a(TBP-2-173);
t-Butyl-4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)-2-(pyrrolidin-1- yl)quinazoline-4-yl)piperazine-1-carboxylate 17b(TBP-2-189);
t-Butyl-4-(7-(3-(1H-imidazol-1-yl)propoxy)-6-methoxy-2-(pyrrolidin-1- yl)quinazolin-4-yl)piperazine-1-carboxylate 17c(TBP-2-191);
t-Butyl-4-(7-(3-(1H-imidazol-1-yl)propoxy)-6-methoxy-2-(pyrrolidin-1- yl)quinazoline-4-yl)piperazine-1-carboxylate 17d(TBP-3-47);
t-Butyl-4-(6-methoxy-2-(pyrrolidin-1-yl)-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-4-yl)piperazine-1-carboxylate 17e(TBP-2-145);
4-(3-(6-Methoxy-4-(piperazin-1-yl)-2-(pyrrolidin-1-yl)quinazolin-7- yloxy)propyl)morpholine 18a(TBP-2-179);
7-(3-(1H-Imidazol-1-yl)propoxy)-6-methoxy-4-(piperazin-1-yl)-2-(pyrrolidin- 1-yl)quinazoline 18b(TBP-3-69);
3-((6-Methoxy-4-(piperazin-1-yl)-2-(pyrrolidin-1-yl)quinazolin-7-yl)oxy)-N,N- dimethylpropan-1-amine 18c(TBP-3-49);
4-(3-(6-Methoxy-4-(4-(phenylsulfonyl)piperazin-1-yl)-2-(pyrrolidin-1- yl)quinazolin-7-yloxy)propyl)morpholine 19(TBP-2-185); 4-(4-Benzylpiperazin-1-yl)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)- 2-(pyrrolidin-1-yl)quinazoline 20(TBP-3-57);
3-(4-(4-Benzylpiperazin-1-yl)-6-methoxy-2-(pyrrolidin-1-yl)quinazolin-7- yloxy)-N,N-dimethylpropan-1-amine 21a(TBP-3-59);
(4-(7-(3-(Dimethylamino)propoxy)-6-methoxy-2-(pyrrolidin-1-yl)quinazolin-4- yl)piperazin-1-yl)(phenyl)methanone 21b(TBP-3-71);
4-(4-Cyclopentylpiperazin-1-yl)-6-methoxy-N-(4-methoxybenzyl)-7-(3- (pyrrolidin-1-yl)propoxy)quinazolin-2-amine 25a(TBP-3-91);
4-(4-Cyclopentylpiperazin-1-yl)-N-(4-fluorobenzyl)-6-methoxy-7-(3- (pyrrolidin-1-yl)propoxy)quinazolin-2-amine 25b(TBP-3-93);
4-(4-Cyclopentylpiperazin-1-yl)-6-methoxy-N-(3-(4-methylpiperazin-1- yl)propyl)-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-2-amine 25c(TBP-3-95); N-(3-(1H-Imidazol-1-yl)propyl)-4-(4-cyclopentylpiperazin-1-yl)-6-methoxy-7- (3-(pyrrolidin-1-yl)propoxy)quinazolin-2-amine 25d(TBP-3-97);
4-(4-Cyclopentylpiperazin-1-yl)-6-methoxy-2-(4-methylpiperazin-1-yl)-7-(3- (pyrrolidin-1-yl)propoxy)quinazoline 25e(TBP-3-99);
7-(Cyclopentyloxy)-6-methoxy-N,N-dimethyl-4-(piperazin-1-yl)quinazolin-2- amine 27 (TBP-3-149);
7-(Cyclopentyloxy)-6-methoxy-N,N-dimethyl-4-(4-methylpiperazin-1- yl)quinazolin-2-amine 28a (TBP-4-11);
1-(4-(7-(Cyclopentyloxy)-2-(dimethylamino)-6-methoxyquinazolin-4- yl)piperazin-1-yl)-2-methylpropan-1-one 28b (TBP-3-155);
4-(7-(Cyclopentyloxy)-2-(dimethylamino)-6-methoxyquinazolin-4-yl)-N,N- dimethylpiperazine-1-carboxamide 28c (TBP-3-157);
6-methoxy-N,N-dimethyl-4-(4-methylpiperazin-1-yl)-7-(piperidin-4- yloxy)quinazolin-2-amine28d (TBP-4-67);
6-methoxy-N,N-dimethyl-4-(4-methylpiperazin-1-yl)-7-((1-methylpiperidin-4- yl)oxy)quinazolin-2-amine28e (TBP-4-69); 6-methoxy-N,N-dimethyl-4-(4-methylpiperazin-1-yl)-7-((1-methylpyrrolidin-3- yl)oxy)quinazolin-2-amine 28f (TBP-4-71);
7-(4-(dimethylamino)phenoxy)-6-methoxy-N,N-dimethyl-4-(4- methylpiperazin-1-yl)quinazolin-2-amine 28g (TBP-4-73);
4-(4-cyclopentylpiperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(1- methylpiperidin-4-yloxy)quinazolin-2-amine 28h (TBP-4-77);
4-(4-cyclopentylpiperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(1- methylpyrrolidin-3-yloxy)quinazolin-2-amine 28i (TBP-4-79);
7-(Benzyloxy)-6-methoxy-N,N-dimethyl-4-(piperazin-1-yl)quinazolin-2-amine 29a (TBP-2-159);
(4-(7-(Benzyloxy)-2-(dimethylamino)-6-methoxyquinazolin-4-yl)piperazin-1- yl)(phenyl)methanone 30a (TBP-3-135);
4-(7-(Benzyloxy)-2-(dimethylamino)-6-methoxyquinazolin-4-yl)-N,N- dimethylpiperazine-1-sulfonamide 30b (TBP-3-137);
7-(Benzyloxy)-6-methoxy-4-(piperazin-1-yl)-2-(pyrrolidin-1-yl)quinazoline 30c (TBP-2-149);
(4-(7-(Benzyloxy)-6-methoxy-2-(pyrrolidin-1-yl)quinazolin-4-yl)piperazin-1- yl)(phenyl)methanone31 (TBP-2-151);
t-Butyl-4-(7-(benzyloxy)-6-methoxy-2-((4-methoxybenzyl)amino)quinazolin-4- yl)piperazine-1-carboxylate 32a (TBP-3-121);
t-Butyl-4-(7-(benzyloxy)-2-((2-hydroxy-2-methylpropyl)amino)-6- methoxyquinazolin-4-yl)piperazine-1-carboxylate 32b (TBP-3-145);
7-(Benzyloxy)-6-methoxy-2-(4-methoxyphenethyl)-4-(piperazin-1- yl)quinazoline33(TBP-3-123);
7-(Benzyloxy)-6-methoxy-2-(4-methoxyphenethyl)-4-(4-methylpiperazin-1- yl)quinazoline 34a (TBP-3-127);
(4-(7-(Benzyloxy)-6-methoxy-2-(4-methoxyphenethyl)quinazolin-4- yl)piperazin-1-yl)(phenyl)methanone 34b (TBP-3-139), tert-butyl 4-(2-(dimethylamino)-7-hydroxy-6-methoxyquinazolin-4- yl)piperazine-carboxylate 9 (TBP-2-71),
4-(4-cyclopentylpiperazin-1-yl)-2-(dimethylamino)-6-methoxyquinazolin-7-ol (TBP-4-75),
tert-butyl 4-(7-hydroxy-6-methoxy-2-(pyrrolidin-1-yl)quinazolin-4- yl)piperazine-1-carboxylate 15 (TBP-2-135)
(4-(7-hydroxy-6-methoxy-2-(pyrrolidin-1-yl)quinazolin-4-yl)piperazin-1- yl)(phenyl)methanone (TBP-2-151),
2-(dimethylamino)-6-methoxy-4-(4-methylpiperazin-1-yl)quinazolin-7-ol (TBP-4-9),
2-(dimethylamino)-6-methoxy-4-(piperazin-1-yl)quinazolin-7-ol (TBP-2-169), tert-butyl 4-(2-(dimethylamino)-6-methoxy-7-(3- morpholinopropoxy)quinazolin-4-yl)piperazine-1-carboxylate (TBP-2-165), tert-butyl 4-(2-(dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-4-yl)piperazine-1-carboxylate 11 (TBP-2-79),
In another embodiment the tructural formulae of general formula 1 is consisting the representative compounds :
Figure imgf000013_0001
Figure imgf000014_0001
Figure imgf000015_0001
Figure imgf000016_0001
Figure imgf000017_0001
Figure imgf000018_0001
Figure imgf000018_0002
Figure imgf000019_0001
Figure imgf000019_0002
Figure imgf000019_0003
Figure imgf000020_0001
In another embodiment the process for the preparation of compounds of formula 1 comprising the steps of:
a. reacting compound of 6 with Boc-piperazxine to obtain compound 7;
b. reacting compound 7 obtained in step a) with amine to obtain compound of formula 8 or 14 or 32;
c. reacting compound 8 or 14 or 32 of step b) either with with hydrogen in presence of Pd/C to obtain compound of 9 or 15 or reacting with TFA to obtain 29a or 29b or 33 ; d. reacting compound 9 or 15 of step c) either with 1-chloro-3-bromopropane or bromocyclopentane to obtain compound 10 or 26 or 16 ;
e. reacting compound 10 or 16 of step d) with amine to compound 11 or 17; f. reacting compound 11 or 17 of step e) or compound 26 of step d) or compound 14 of step b) with TFA to obtain 12 or 18 or 27;
g. reacting compound 12obtained in step f) or 29aor 29b of step c) with sulphonly chloride, alkly or aryl carboxylic acid or alkyl halide or aldehyde or reacting compound 33 of step c) with alkyl halide or benzoic acid to obtain the compound of formula 1. In another embodiment, further comprises, reacting compound 27 of step f) with alkyl halide or acid chloride to obtain compound of formula 1 or compound 31;
In another embodiment, the compound 31 further reacted with hydrogen in presence of Pd/C to obtain compound of formula 1.
In another embodiment, the process further comprising(i) reacting compound 6 with N- cyclopentylpiperazine or N-methyl piperazine followed by dimethyl amine to obtain an interemediate
(ii) reacting the intermediate with hydrogen in presence of Pd/C to obtain compound 22 or 9b or 9c; and
(iii)reacting compound 22, 9b or 9c with 1-(3-chloropropyl)pyrrolidine or bromaamine or 4-hydroxy amine to obtain compound of formula 1.
In another embodiment, the amine used in step b) r step e) is selected from the group consisting of,
Figure imgf000021_0001
In another embodiment,the sulphonyl chloride is selected from the group consisting of,
Figure imgf000022_0001
In another embodiment,the alkyl or aryl carboxylic acid or acid chloride is selected from the group consisting of,
Figure imgf000022_0002
In another embodiment,the alkyl halide is selected from the group consisting of,
Figure imgf000022_0003
In another embodiment,the alkyl o aryl aldehyde is selected from the group consisting of,
Figure imgf000022_0004
In another embodiment of the present invention, a general screening method is provided involving human peripheral blood mononuclear cells to screen compounds of general formula I against all TLRs. In another embodiment of the present invention, a method is provided for testing TLR9 antagonism of compounds of general formula I, in primary human plasmacytoid dendritic cells (pDCs) purified from human peripheral blood mononuclear cells. In yet another embodiment of the present invention, a reporter assay method is provided involving a cell line expressing TLR9 to screen compounds of general formula I for TLR9 antagonism.
Assays results involving human peripheral blood mononuclear cells, human primary pDCs and transfected TLR9 cells are correlating. In yet another embodiment of the present invention, said compoundswith formula (I) described by the presentinvention affect immune stimulation via interaction with aTLR9. In yet another embodiment of the present invention, it is believedthat many of the small molecules described by the presentinvention inhibit immune stimulation via TLR9 antagonism. In yet another embodiment of the present invention, the methods of theinvention are useful whenever it is desirable to alter TLR9mediated signalling in response to a suitable TLR ligand orTLR signalling agonist. In yet another embodiment of the present invention, it is believed that the said compounds with formula (I) can be useful to inhibit an immune stimulatory nucleic acid associated response in a subject. In yet another embodiment of the present invention, it is believed that the said compounds with formula (I) shows TLR9 antagonistic activity that can modulate autoreactive inflammation in different autoimmune diseases since aberrant TLR9 activation is implicated in such diseases. In yet another embodiment of the present invention, it is believed that the said compounds with formula (I)can be used in a number of clinical applications, including as pharmaceutical agents and methods for treating conditions involving unwanted immune activity due to TLR9 activation. In yet another embodiment of the present invention, the said compounds with formula (I) are without considerable cytotoxicity in HepG2 (a hepatic epithelial cell line) and SW480 (an intestinal mucosal epithelial cell line) cells at concentrations below 100 µM. In yet another embodiment of the present invention, it is believed that the said compounds with formula (I) can be useful in the treatment of different clinical context of autoreactive inflammation, inflammation, allergy,asthma, graft rejection, and GvHD where aberrant TLR9 activation is present. In yet another embodiment of the present invention, the small molecules with formula (I) is believed to affect TLRs directly and thus affect TLR-bearing cells, such as antigen-presenting cells (APCs), such agents can be used in conjunction with additional agents which affect non-APC immune cells, such as T lymphocytes (T cells). This will provide immune modulatory intervention at two levels: innate immunity and acquired immunity. The combination intervention is synergistic, since innate immunity is believed to initiate and support acquired immunity. In one aspect of the invention, a method of affecting TLR mediated signalling in response to a TLR ligand is provided. The method according to this aspect involves detecting TLR9 antagonism of effective amount of a compound of Formula (I) using a reporter cell line that reports nuclear factor kappa B expression downstream of TLR9 signalling. BRIEF DESCRIPTION OF ACCOMPANYING DRAWING
Fig.1:-Structural evolution of the quinazoline scaffold (FORMULA I) small molecules along with respective TLR9-antagonistic activity. The figure denotes percent interferon alpha production in response to TLR9-agonist ODN2216 from human peripheral blood mononuclear cells in the presence of different doses of the antagonist molecules (0, 0.1, 1, 5, 10µM). Each row represents a single molecule with increasing antagonist concentrations from left to right as shown in the figure. TLR9-antagonist activity of one representative molecule belonging to each structural subset is indicated. Fig.2: TLR9 inhibition in pDCs by selected compounds with formula (I). The graphs denote dose-dependent reduction in IFN-α production in response to TLR9- agonist ODN2216 from human plasmacytoid dendritic cells (pDC) in the presence of different doses of the antagonist molecules. Each data is derived from two donors. Average values are reported.
Fig.3: TLR9 inhibition inHEK-Blue-hTLR9 reporter cell line by selected compounds with formula (I). The graphs denote dose-dependent inhibition of TLR9 activation in a HEK-Blue-hTLR9 reporter cell line in the presence of different doses of the antagonist molecules, which is represented in terms of decrease in SEAP activity. Data shown are mean of triplicate wells ± SD.
Fig.4: Cytotoxicity based on MTT assay of the identified TLR9 antagonist molecules.HepG2 and SW480 cells were cultured in presence of different concentrations (0.1, 0.5,1, 10, 20 and 100 µM) of different candidate small molecule antagonists for 24 hrs. At 24 hrs MTT assay was performed as described in the text. Respective absorbance at 570nm is represented. Each line represents a specific small molecule as denoted in the legend.
Table 1 depicts overall structure of the compounds with quinazoline scaffold with formula (I) composition of the Invention
Table 2 depicts IC50 values of the compounds with quinazoline scaffold with formula (I) composition of the Invention.
DETAILED DESCRIPTION OF THE INVENTION
In the present invention the synthesis of compounds of general formula I was prepared as follows.
Intermediate 6 was synthesized through the 5 steps synthetic sequences as shown in Example 1, from commercially available 3-methoxy-4-hydroxybenzonitrile. Benzylation of compound 1 followed by nitration and reduction produces 4- (benzyloxy)-5-methoxy-2-nitrobenzonitrile 4, which upon amine amide coupling by CDI reagent forms quinazolinedione derivative 5. On POCl3 treatment 5 was converted to the intermediate 2,4-dichloroquinazoline derivative 6. Derivatives 13 were prepared via 7 steps from the dichloroquinazoline intermediate 6 (Example 1). On treatment with Bocpiperizine followed by dimethylamine addition 6 was converted to diaminosubstituted quinazoline 8. On debenzylation by Pd/C and hydrogen gas of 8 followed by SN2 reaction by 1-bromo-3-chloropropane and pyrrolidine substitution at 7-position of quinazoline afforded compound 11. Boc group deprotection using TFA and subsequent sulphonyl chloride substitution afforded compounds 13a, 13b and benzylbromide, bromocyclopentane, bromomethylcyclopentane substitution afforded 13g, 13e, 13d, and carboxylic acid coupling reactions with the corresponding secondary amine using HATU produces the derivatives 13c, 13f. Compound 7 on substitution by pyrrolidine followed by hydrogenation and SN2 reaction by 1-bromo-3-chloropropane gave compound 16, which upon treatmentwith different bases providedcompounds 17 series as shown in Scheme 3. Boc groupdeprotection using TFA afforded derivatives 18a, 18b, and 18c (Scheme 4). Compound 6 on treatment with 1-cyclopentylpiperazine followed by hydrogenation and 1-(3-chloropropyl)pyrrolidine attachment provided compound 24, which upon treatment with different bases at 2-possition in quinazoline scaffold gave the 25 derivative series (Scheme-6). Following the above reaction procedure few more derivatives (28a, 28b, 28c, 30a, 30b, 32a, 32b, 34a, 34b) containing different substitution at the three variable position of quinazoline have been synthesized in Scheme-7, 8,9 and 10. The synthesized compounds of general formula I were screened for toll-like receptor 9 antagonistic activities by a medium throughput biological assay based on toll-like receptor 9 activation in primary human immune cells. Type A and type B unmethylated cytosine-guanine rich DNA oligonucleotides (CpG oligonucleotides) are the bona fide ligands for TLR 9. On activation of TLR9 by CpG oligonucleotides, type I interferons (e.g. IFN-alpha) are released. The synthesized compounds of general formula I was able to alter the release of type I interferons (e.g. IFN-alpha). Type I interferons(IFN-alpha) production from human peripheral blood mononuclear cells in response to type A CpG oligonucleotides (CpGA) almost exclusively results from TLR9 triggering on the PDCs. Based on this principle the screening assay was designed where we isolated peripheral blood mononuclear cells (PBMCs) from venous blood collected from healthy donors using density gradient centrifugation. The synthesized compounds of general formula I having TLR9 antagonistic activity inhibited IFN-alpha production in this screening assay. The synthesized compounds of general formula I were screened for toll-like receptor 9 antagonistic activities by a medium throughput biological assay based on toll-like receptor 9 activation in plasmacytoid dendritic cells (pDC) which were isolated from PBMCs of healthy donors. The synthesized compounds of general formula I having TLR9 antagonistic activity inhibited IFN-alpha production in response to CpGA in this screening assay. The synthesized compounds of general formula I were screened for toll-like receptor 9 antagonism using a HEK-Blue- hTLR9 Secreted Alkaline Phosphatase (SEAP) reporter assay. The synthesized compounds of general formula I having TLR9 antagonistic activity inhibited TLR9-mediated NF-kB activation in a dose-dependent manner.
The synthesized compounds of general formula I werescreened for cytotoxicity.MTT assay is a colorimetric assay for assessing cell viability. HepG2 (a hepatic epithelial cell line) and SW480 (an intestinal mucosal epithelial cell line) cells were used to check cytotoxicity. The synthesized compounds of general formula I did not show any considerable cytotoxicity at concentrations below 100uM on this assay (Figure 4). EXPERIMENTAL DETAILS:
The following examples are intended for illustrative purposes only and are not to be construed as being limitations for the invention thereon in any manner. Temperatures are given in degree Celsius. The structure of final products, intermediates and starting materials is confirmed by standard analytical methods, e.g. spectroscopic characterization, e.g., MS, NMR. Abbreviations used are those conventional in the art. All starting materials, reagents, catalysts, building blocks, acids, bases, dehydrating agent and solvents utilized to synthesize the compounds of the present invention are either commercially available or can be produced by known organic synthesis methods in the art. Abbreviations
BnBr Benzylbromide DMF N,N-dimethylformamide
AcOH Acetic acid
CDI 1,1'-Carbonyldiimidazole
POCl3 phosphorous oxychloride
DIPEA N,N-Diisopropylethylamine
DCM Dichloromethane
TFA Trifluoroacetic acid
DMSO Dimethyl sulfoxide
Boc Tert butyl carbamate
THF Tetrahydrofurane
HATU 1-[Bis(dimethylamino)methylene]-1H- 1,2,3-triazolo[4,5-b]pyridinium-3-oxid hexafluorophosphate
HBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3- tetramethyluronium hexafluorophosphate)
EXAMPLES
Example 1
Figure imgf000029_0001
4-(Benzyloxy)-3-methoxybenzonitrile (2): 4-hydroxy-3-methoxybenzonitrile (10.0 g, 67.11 mmol) and potassium carbonate (19 g, 134 mmol) were taken in DryDMF (20 mL) at 0˚C. And then benzyl bromide (9.0 mL, 80.5 mmol) was added to the reaction mixture very slowly. The reaction mixture was stirred 12 h at room temperature, and brine solution (100 mL) was added. The resulting precipitate was collected, washed with water and dried to provide 4-benzyloxy-3-methoxybenzonitrileas a white solid (13.9 g, 89% yield). 1H NMR (300MHz, CDCl3) δ 3.88 (s, 3H), 5.18 (s, 2H),6.88 (d, J=8.4 Hz, 1H),7.03 (s, 1H),7.21 (dd, J=8.4, 2.0 Hz, 1H),7.32-7.42 (m, 5H). ESI [M+Na]+: 262.25). 4-(Benzyloxy)-5-methoxy-2-nitrobenzonitrile (3): To an ice cold solution of compound 2 (8.0 g, 33.6 mmol) in 20 mL acetic acid, 69% Nitric acid (126.4 mmol) was added dropwise. Reaction mixture was slowly allowed to come at room temperature and kept in that condition 22 h. The reaction mixture was neutralized with 4N NaOH solution and then residue was extracted with DCM, washed with brine and dried over sodium sulphate. Concentrating DCM part provide compound 3 as a yellow solid (6.8 g, 82% yield).1H NMR (300MHz, CDCl3) δ 4.01 (s, 3H), 5.26 (s, 2H),7.21(s, 1H),7.36-7.42 (m, 5H),7.85 (s.1H).ESI[M+Na]+: 307.14). 2-Amino-4-(benzyloxy)-5-methoxybenzamide (4): A mixture of compound 3 (5.0 g, 17.6 mmol), iron dust (3.0 g, 54.8 mmol), and ammonium chloride (3.8 g, 70.4 mmol) in isopropyl alcohol-water (2:1) 50 mL was heated to reflux for 4 h. Then, the reaction mixture filtered through celite and the filtrate part was extracted with 5% methanol in DCM. The organic part was dried, concentrated and purified by silica gel chromatography with 10% methanol in DCM to afford compound 4 as light yellow solid (2.7 g, 52% yield). 1H NMR (300 MHz, CDCl3) δ 3.89 (s, 3H),5.15 (s, 2H),6.20 (s, 1H),6.88 (s, 1H),7.29-7.51 (m, 5H).FAB [M+H]+: 272.6. 7-(Benzyloxy)-6-methoxyquinazoline-2,4-diol (5): Compound 4 (2.0 g, 61 mmol) was taken in dry THF, to the clean solution CDI (8.05 mmol) was added and the reaction mixture was heated at 75˚C. A precipitate formed and the reaction was continued for 8hr for complete consumption of starting material. The precipitate was filtered and washed with THF to afford compound 5 (1.85, 82% yield) as a yellow solid. 1H NMR (300 MHz, DMSO-d6) δ 3.86 (s, 3H), 5.14 (s, 2H),6.79 (s, 1H),7.28 (s, 1H),7.28-7.48 (m, 5H). FAB[M+H]+:299.2. 7-(Benzyloxy)-2,4-dichloro-6-methoxyquinazoline (6): Compound 5 (2 g, 6.71 mmol) was taken in 5 mL N,N-diethylaniline, the reaction mixture was cooled to 0˚C. Then POCl3 (10 mL) was added very slowly and the reaction mixture was stirred at 110˚C- 120˚C for overnight. The reaction mixture was was neutralized with saturated sodium bicarbonate aqueous solution. The resulting mixture was extracted with chloroform. The organic solvents were dried, concentrated, and purified by silica gel chromatography (hexane to 20% ethyl acetate in hexanes) to give compound 6 as a light yellow solid (1.40 g, 61% yield). 1H NMR (300 MHz, CDCl3) δ 4.06 (s, 3H), 5.31 (s, 2H),7.26 (s, 1H),7.30 (s, 1H),7.33-7.51 (m, 5H).FAB[M+H]+:335.2.
Example 2
Figure imgf000032_0001
Figure imgf000032_0002
t-Butyl-4-(7-(benzyloxy-2-chloro-6-methoxyquinazoline-4-yl)piperazine-1- carboxylate (7): N-bocPiperazine(620 mg, 0.003 mmol) was added to a stirred solution of 6 (1 g, 0.0029 mmol) in dry 1,4-Dioxane and DIPEA (0.7 mL,0.005 mmol). . The solution was stirred for 30 min at room temperature. After adding water a precipitate was formed which was filtered to give compound 7 (1.2g, 86% yield) as white solid (m.p-155-158Û&1^H^ N^MR (300 MHz, CDCl3) ^ 1.52 (s, 9H),3.63 (m, 4H),3.69 (m, 4H),3.97 (s, 3H),5.27 (s, 2H),7.05 (s, 1H),7.21 (s, 1H),7.33-7.41(m, 3H),7.44-7.47 (m, 2H).EI-HRMS[M]+: Calculated: 484.1877. Found: 484.1877. t-Butyl4-(7-(benzyloxy)-2-(dimethylamino)-6-methoxyquinazolin-4yl)piperazine-1- carboxylate (8): 2M dimethylamine in THF (1mL, 2mmol)) was added to a solution of compound 7 (250 mg, 0.52 mmol) in dryTHF (2 mL) and the reaction mixture was stirred for 10 h DW^^^Û&^LQ^FV wHasD reOmHovGed^ unWdeXr E vacHuu^m^, th7e+ residue then dissolved in ethyl acetate and the organic layer was washed with water and brine, dried and concentrated to give compound 8 (220 mg, 87% yield) as a white solid (m.p- 192-195Û& 1^H^ NMR (300 MHz, CDCl3) ^ 1.52 (s, 9H), 3.21(s, 6H), 3.63 (t,J = 6 Hz, 4H), 3.69 (t,J = 6 Hz, 4H), 3.97 (s, 3H), 5.27 (s, 2H), 6.98 (s, 1H), 7.08 (s, 1H), 7.31- 7.38 (m, 3H), 7.41-7.49 (m, 2H). EI-HRMS[M]+: Calculated:493.2689. Found: 494.2757. t-Butyl-4-(2-(dimethylamino)-7-hydroxy-6-methoxyquinazolin-4yl)piperazine-1- carboxylate (9): 10% Pd/C (50 mg) was added to a solution of compound 8 (500 mg, 0.08 mmol) in MeOH 10 mL followed by the addition of 1 mL DIPEA. A hydrogen balloon was attached and the mixture was stirred at room temperature for 3h. The reaction mixture was filtered through celite and washed with methanol until the filtrate became colourless. The solution was concentrated to provide compound 9 (330 mg, 82% yield) as pale yellow solid (m.p-254-256Û&^GpHosFe)R. 1PH NMR (300 MHz, CDCl3) ^1.31 (s, 9H), 3.16 (s, 6H), 3.47-3.51 (m, 4H), 3.75 (s, 3H), 3.80-3.83 (m, 4H), 6.86 (s, 1H), 7.29 (s, 1H), EI-HRMS[M]+: Calculated:403.2220. Found: 403.2219. t-Butyl-4-(7-(3-chloropropoxy)-2-(dimethylamino)-6methoxyquinazolin- 4yl)piperazine-1-carboxylate (10): Compound 9 (200 mg, 0.65 mmol) and potassium carbonate (200 mg, 1.43 mmol) was taken in dryDMF (5 mL). The reaction mixture was stirred at room temperature for 30 mins. Then 1-bromo-3-chloropropane (7.2 µL, 0.72 mmol) was added and the mixture was stirred at 110˚C for 12 h. The reaction mixture was extracted with ethyl acetate and washed with 50 mL of water followed by brine wash, dried with sodium sulphate and concentrated. The residue was purified by silica gel flash column chromatography, eluting with 60% ethyl acetate in hexane, to give compound 10 (169 mg, 72% yield) as a colourless gummy solid. 1H NMR (300 MHz, CDCl3) ^1.49 (s, 9H), 2.45-2.31 (m, 2H),3.22 (s, 6H), 3.63 (t,J = 6 Hz, 4H),3.69 (t,J = 6 Hz, 4H),3.79-3.77 (t, J = 6 Hz, 2H),3.88 (s, 3H),4.29-4.24 (m, 2H),6.96 (s, 2H), 7.08 (s, 1H). EI-HRMS[M]+: Calculated: 479.2299 Found: 479.2297. t-Butyl-4-(2-(dimethylamino)-6-methoxy-7-(3-(pyrrolidine-1-yl) propoxy) quinazoline-4-yl) piperazine-1-carboxylate (11): To a solution of compound 10 (150 mg, 0.33 mmol) in 2 mL dryDMF I a sealed tube pyrroline (2.8 µL, 0.34 mmol) was added and the reaction mixture was heated at 90˚C for 12 h. The reaction mixture was extracted with ethyl acetate and washed with 50mL of water followed by brine wash; ethyl acetate part was dried with sodium sulphate and concentrated. The residue was purified by silica gel flash column chromatography, eluting with 20% CMA (NH3: MeOH: CHCl3 = 5:10:85) in chloroform, to give compound 11 as a gummy solid. 1H NMR (300 MHz, CDCl3) ^1.49 (s, 9H),2.45-2.31 (m, 2H),3.22(s, 6H),3.63 (br. s, 4H),3.69 (br. s, 4H),3.79-3.77 (m, 2H),3.88 (s, 3H),4.31 (t,J = 6.2 Hz, 2H),7.2 (s, 2H),7.99 (s, 1H). EI-HRMS[M]+: Calculated: 514.3268 Found: 514.3270. 6-Methoxy-N,N-dimethyl-4-(piperazin-1-yl)-7-(3-(pyrrolidin- 1yl)propoxy)quinazolin-2-amine (12) : To a solution of compound 11(100 mg, 0.19 mmol) in 2mL dry DCM 0.5 mL TFA was added at 0˚C and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was quenched by adding 2 (N) NaOH solution, then the mixture was extracted with DCM and washed the organic part with brine, dried over sodium sulphate, concentrating the organic part gives compound 12 as pure colourless solid (70 mg, 67% yield). EI-HRMS[M]+: Calculated: 414.2743 Found: 414.2741 General procedure for the synthesis of compound 13a, 13b: To a solution of compound 12 (50 mg, 0.12 mmol) in 2 mL dryDCM, DIPEA (0.1 mL, 0.24 mmol) and 1.5eqv of sulphonyl chloride were added keeping the reaction mixture in 0˚C. Then it was stirred at room temperaturefor 4hrs. Reaction mixture was washed with water and extracted in DCM. Concentrating the organic part gives a mixture. Purification using chloroform-methanol (15%) gives the corresponding compounds as solid. General procedure for the synthesis of compound 13c, 13f, 13h and 13i: Carboxylic acid (1.0 eqv.) was taken in 2 mL dryDMF followed by the addition of HATU/HBTU (1.5eqv.) and DIPEA (1.5eqv.). The reaction mixture was stirred at room temperature for 30mins. Then compound 12 (50 mg, 0.12 mmol, 1.1eqv.) in dry DMF was added. Reaction mixture at stirred at room temperature for overnight. The reaction mixture was extracted with ethyl acetate and washed with excess of water followed by brine wash; ethyl acetate part was dried with sodium sulphate and concentrated. The residue was purified by flash column to provide compound 13c, 13f, 13h,13i. General procedure for the synthesis of compound 13d and 13g: To a solution of compound 12 (80 mg, 0.19 mmol) in dry toluene corresponding aldehydes (cyclopentanecarboxaldehyde and benzaldehyde, 2 eqv.) and activated molecular sieves (4A) were added and the reaction mixture was refluxed for 12 h. Toluene was removed in vacuum and dry DCE was added followed by the addition of Sodium triacetoxyborohydride (2 eqv.). This reaction mixture was stirred at room temperature for 4 h. Saturated NaHCO3 solution was added and extracted with chloroform. The organic layer was washed with brine, dried over sodium sulphate and concentrated. The residue was purified by flash column to provide pure corresponding derivatives. Procedure for the synthesis of compound 13e: To a solution of compound 12 (80 mg, 0.19 mmol) in 5 mL dry DMF bromocyclopentane (3.1 µL, 0.28mmol) was added followed by the addition of potassium carbonate ( 58 mg, 0.38mmol) and the reaction mixture was stirred at room temperature for 10 h.50 mL water was added and extracted with ethylacetate. The organic layer was washed with brine, dried over sodium sulphate and concentrated. The residue was purified by flash column to provide compound 13e as gummy solid. 4-(4-(Isopropylsulfonyl)piperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(3-(pyrrolidin- 1-yl)propoxy)quinazolin-2-amine (13a): 1H NMR (300 MHz, CDCl3) ^ 1.25 (br. s, 6H), 1.38 (d, J= 5.49 Hz, 6H), 2.06 (br. s, 4H), 2.34 (br. s, 2H), 3.23 (br. s, 6H), 3.55 (br. s, 4H), 3.66 (br. s, 5H), 3.88 (br. s, 3H), 4.20 (br. s, 2H), 6.91 (br. s, 1H), 7.00 (br. s, 1H). EI-HRMS[M]+: Calculated: 520.2832. Found: 520.2838. 4-(4-(Dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1yl)propoxy)quinazolin-4-yl)- N,N-dimethylpiperazin-1-sulfonamide (13b):1H NMR (600 MHz, CDCl3) ^ 1.73 - 1.75 (m, 2H), 1.82 (br. s., 6H), 2.13 - 2.17 (m, 2H), 2.62 (br. s, 2H), 2.68 - 2.75 (m, 2H), 2.87 (s, 6H), 3.21 (s, 6H), 3.42 - 3.44 (m, 2H), 3.59 - 3.63 (m, 4H), 3.88 (s, 3H), 4.18 - 4.20 (m, 2H), 6.92 (s, 1H), 6.96 (s, 1H). EI-HRMS[M]+: Calculated: 521.2784. Found: 521.2789. Cyclopentyl-(4-(2-(dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-4-yl)piperazine-1yl)methanone (13c): (35 mg, 55% yield).1H NMR (300 MHz, CDCl3) ^ 1.60 (dd, J=7.16, 4.52 Hz, 2H), 1.75 (d, J=6.03 Hz, 2H), 1.86 (d, J=5.27 Hz, 8H), 2.21 (d, J=3.77 Hz, 1H), 2.59 (t, J=6.40 Hz, 2H), 2.74 (br. s, 2H), 2.81 (br. s, 2H), 2.93 (d, J=7.91 Hz, 2H), 3.22 (s, 6H), 3.57 (br. s, 4H), 3.74 (br. s, 2H), 3.83 (br. s, 2H), 3.89 (s, 3H), 4.19 (t, J=6.40 Hz, 2H), 6.96 (s, 2H). EI-HRMS[M]+: Calculated: 510.3318. Found: 510.3311. 4-(4-(Cyclopentylmethyl)piperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(3- (pyrrolidin-1yl)propoxy)quinazolin-2-amine (13d): 1H NMR (300 MHz, CDCl3) ^1.20 - 1.28 (m, 2H), 1.58 (dd, J=17.05, 7.25 Hz, 5H), 1.81 (br. s, 6H), 2.13 (d, J=6.97 Hz, 2H), 2.34 (d, J=7.35 Hz, 2H), 2.56 - 2.63 (m, 8H), 2.66 - 2.71 (m, 2H), 3.16 - 3.26 (m, 6H), 3.51 - 3.63 (m, 4H), 3.91 (s, 3H), 4.17 - 4.22 (m, 2H), 6.94 (br. s, 1H), 6.99 (s, 1H). ESI [M+H]+:497.73. 4-(4-(Cyclopentylpiperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(3-(pyrrolidin- 1yl)propoxy)quinazolin-2-amine (13e):1H NMR (300 MHz, CDCl3) δ 1.40 (d, J= 8.29 Hz, 2H), 1.43 - 1.55 (m, 2H), 1.64 (d, J= 4.14 Hz, 2H), 1.77 (br. s, 6H), 2.08 - 2.14 (m, 2H), 2.48 (d, J= 7.72 Hz, 1H), 2.55 - 2.64 (m, 8H), 2.67 (d, J= 7.72 Hz, 2H), 3.14 (s, 6H), 3.54 (d, J= 13.75 Hz, 4H), 3.81 (s, 3H), 4.12 (t, J=6.50 Hz, 2H), 6.86 (s, 1H), 6.94 (s, 1H). ESI [M+H]+:483.55. (4-(2-(Dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline-4- yl)piperazin-1-yl)(phenyl)methanone (13f):1H NMR (600 MHz, CDCl3) δ 1.86 (br. s, 4H), 2.15 - 2.19 (m, 2H), 2.75 (br. s, 4H), 2.83 (t, J= 7.34 Hz, 2H), 3.19 (s, 6H), 3.45 - 3.70 (m, 8H), 3.86 (s, 3H), 4.18 (t, J= 6.38 Hz, 2H), 6.94 (d, J= 7.56 Hz, 2H), 7.42 (s, 5H). ESI [M+H]+:519.61. 4-(4-Benzylpiperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-2-amine (13g): 1H NMR (600 MHz, CDCl3) δ 1.79 (t, J= 3.23 Hz, 4H), 2.09 - 2.15 (m, 2H), 2.55 (br. s, 4H), 2.62 - 2.67 (m, 6H), 3.20 (s, 6H), 3.58 (s, 2H), 3.58 - 3.63 (m, 4H), 3.86 (s, 3H), 4.17 (t, J= 6.71 Hz, 2H), 6.96 (d, J= 11.15 Hz, 2H), 7.25 - 7.28 (m, 1H), 7.31 - 7.37 (m, 4H). EI-HRMS[M]+: 504.3198. (4-(Aminomethyl)phenyl)(4-(2-(dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-4-yl)piperazin-1-yl)methanone(13h):1H NMR (300 MHz, CDCl3) δ 1.81 (t, J = 6.6 Hz, 4H), 2.08-2.17 (m, 4H), 2.57 (t, J = 6 Hz, 4H), 2.68 (t, J = 7.2 Hz, 2H), 3.20 (s, 6H), 3.54-3.64 (m, 6H), 3.87 (s, 3H), 3.93 (d, J = 13.8 Hz, 2H), 4.19 (t, J = 6.6 Hz, 2H), 6.94 (d, J = 6.6 Hz, 2H), 7.36-7.43 (m, 4H). ESI [M+H]+:548.40. 6-((4-(4-(2-(Dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin- 4-yl)piperazine-1-carbonyl)benzyl)amino)-6-oxohexanoic acid(13i): 1H NMR (300 MHz, CDCl3) δ 1.58-1.66 (m, 4H), 1.94 (t, J = 6 Hz, 4H), 2.18-2.27 (m, 6H), 3.00 (t, J = 9.9 Hz, 6H), 3.18 (s, 6H), 3.59 (br. s, 6H), 3.85 (s, 3H), 4.01 (br. s, 2H), 4.15 (t, J = 6 Hz, 2H), 4.43 (d, J = 6 Hz, 2H), 6.92 (d, J = 6.3 Hz, 2H), 7.29-7.35 (m, 4H), 7.41 (br. s, 1H).ESI [M+H]+:676.19 Example 3
Figure imgf000038_0001
t-Butyl-4-(7-(benzyloxy)-6-methoxy-2-(pyrrolidin-1-yl)quinazoline-4-yl)piperazine- 1-carboxylate (14): Pyrrolidine(0.1 mL, 1.24 mmol was added to a solution of compound 7 (500 mg, 1.03 mmol) in dry1,4-Dioxane (10 mL) and the reaction mixture was stirred for 12 h at 110˚C. Dioxane was removed under vacuum, the residue then dissolved in ethyl acetate and the organic layer was washed with water and brine, dried and concentrated. The residue was purified by silica gel flash column chromatography, eluting with 30% ethyl acetate in hexane, to give compound to give compound 14 (459 mg, 84% yield) as a brown solid (m.p-188-190˚C).1H NMR (600 MHz, CDCl3) ^1.49 (s, 9H), 1.96 (t, J= 6.53 Hz, 4H), 3.54 (br. s, 4H), 3.60 - 3.63 (m, 8H), 3.89 (s, 3H), 5.22 (s, 2H), 6.98 (s, 1H), 7.04 (s, 1H), 7.31 (d, J= 7.48 Hz, 1H), 7.37 (t, J= 7.56 Hz, 2H), 7.46 (d, J= 7.56 Hz, 2H); 13C NMR (75 MHz, CDCl3) ^28.40, 37.06,49.59,56.18,70.48,79.99,104.47,105.03,106.94,127.44,128.01,128.58,136.22,145. 17,153.91,154.87, 164.74. EI-HRMS[M]+: Calculated: 519.2846. Found: 519.2845. t-Butyl-4-(7-hydroxy-6-methoxy-2-(pyrrolidin-1-yl)quinazoline-4-yl)piperazine-1- carboxylate (15): 10% Pd/C (50 mg) was added to a solution of compound 8 (500 mg, 0.96 mmol) in 10Ml ethanol . A hydrogen balloon was attached and the mixture was stirred at room temperature for 3hrs. The reaction mixture was filtered through celite and washed with methanol until the filtrate became colourless. The filtrate was concentrated and purified by column chromatography eluting by 8% methanol in Chloroform to provide compound 15 ( 345 mg, 82%) as yellowish green solid.1H NMR (300 MHz, CDCl3) δ 1.50 (s, 9H), 1.92 (br. s, 4H), 3.57 (br. s, 4H), 3.61 (br. s, 8H), 3.72 (s, 1H), 3.83 (s, 3H), 6.70 (br. s, 1H), 7.20 (s, 1H);13C NMR (75 MHz, CDCl3) ^25.47,
28.43,49.68,55.60,80.07,103.06,103.36,106.97,144.64,149.46,154.03,154.82,155.49, 164.36. EI-HRMS[M]+: Calculated: 429.2376. Found: 429.2376. t-Butyl-4-(7-(3-chloropropoxy)-6-methoxy-2-(pyrrolidin-1-yl)quinazoline-4- yl)piperazine-1-carboxylate (16): Compound 15 (300 mg, 0.69 mmol) and potassium carbonate (194 mg, 1.39 mmol) was taken in dryDMF (5mL). The reaction mixture was stirred at room temperature for 30 mins. Then 1-bromo-3-chloropropane (8.0 µL, 0.76 mmol) was added and the mixture was stirred at 110˚C for 12 h. The reaction mixture was extracted with ethyl acetate and washed with 50 mL of water followed by brine wash, dried with sodium sulphate and concentrated. The residue was purified by silica gel flash column chromatography, eluting with 2% methanol in chloroform, to give compound 16 (250 mg, 72%) as a colourless gummy solid.1H NMR (300 MHz, CDCl3) ^ 1.50 (s, 9H), 1.97 - 2.02 (m, 4H), 2.33 - 2.39 (m, 2H), 3.60 (br. s, 4H), 3.62 - 3.68 (m, 8H), 3.79 (t, J=6.22 Hz, 2H), 3.90 (s, 3H), 4.26 - 4.32 (m, 2H), 6.98 (s, 1H), 7.07 - 7.16 (m, 1H); 13C NMR (75 MHz, CDCl3) ^56.06, 25.48, 28.35,29.80,31.85,46.54,49.54,85.11,79.81,104.58,105.10,106.45,144.69,151.54,153.75 ,154.78,157.00, 164.71. EI-HRMS[M]+: Calculated: 505.2456. Found: 505.2456. General procedure for the synthesis of compounds 17 series: To a solution of compound 16 (150 mg, 0.29 mmol) in 2 mL dryDMF in a sealed tube corresponding base 1.1eqv was added and the reaction mixture was heated at 90˚C for 10 h. The reaction mixture was extracted with ethyl acetate and washed with 50 mL of water followed by brine wash; ethyl acetate part was dried with sodium sulphate and concentrated. The residue was purified by silica gel flash column chromatography. t-Butyl-4-(6-methoxy-7-(3-morpholinpropoxy)-2-(pyrrolidin-1-yl)quinazoline-4- yl)piperazine-1-carboxylate (17a): Compound (17a) was prepared by the same procedure as 17 as white solid.1H NMR (300 MHz, CDCl3) ^1.49 (s, 9H), 1.98 (t, J=6.40 Hz, 6H), 2.05 - 2.11 (m, 3H), 2.47 (br. s, 4H), 2.53 (s, 2H), 3.56 (br. s, 4H), 3.60 - 3.64 (m, 7H), 3.71 - 3.74 (m, 4H), 3.89 (s, 3H), 4.20 (t, J= 6.59 Hz, 2H), 6.96 (s, 1H), 7.27 (s, 1H). EI-HRMS[M]+: Calculated: 556.3373 Found: 556.3375. t-Butyl-4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)-2-(pyrrolidin-1- yl)quinazoline-4-yl)piperazine-1-carboxylate (17b): 1H NMR (600 MHz, CDCl3) ^ 1.48 (s, 9H), 1.95 - 1.97 (m, 4H), 2.05 - 2.08 (m, 2H), 2.28 (s, 3H), 2.39 - 2.50 (m, 4H), 2.52 (t, J= 7.12 Hz, 4H), 3.53 (br. s, 4H), 3.59 - 3.64 (m, 10H), 3.87 (s, 3H), 4.17 (t, J= 6.71 Hz, 2H), 6.95 (s, 1H), 6.97 (s, 1H). EI-HRMS[M]+: Calculated: 569.3690. Found: 569.3694. t-Butyl-4-(7-(3-(1H-imidazol-1-yl)propoxy)-6-methoxy-2-(pyrrolidin-1- yl)quinazolin-4-yl)piperazine-1-carboxylate (17c): 1H NMR (300 MHz, CDCl3) δ1.47 (s, 9H), 1.96 (br. s, 4H), 2.26 - 2.37 (m, 2H), 3.60 (br. s, 12H), 3.89 (s, 3H), 4.07 (t, J= 5.56 Hz, 2H), 4.20 (t, J= 6.59 Hz, 2H), 6.93 (br. s, 1H), 6.96 (s, 1H), 7.03 (br. s, 1H), 7.06 - 7.13 (m, 1H), 7.50 (br. s, 1H). ESI [M+H]+:538.46. t-Butyl-4-(7-(3-(1H-imidazol-1-yl)propoxy)-6-methoxy-2-(pyrrolidin-1- yl)quinazoline-4-yl)piperazine-1-carboxylate (17d): 1H NMR (300 MHz, CDCl3) ^1.50 (s, 9H), 2.00 (br. s, 4H), 2.31 - 2.39 (m, 2H), 3.66 (d, J= 10.98 Hz, 12H), 3.91 (s, 3H), 4.12 (d, J= 5.49 Hz, 2H), 4.22 (t, J= 6.49 Hz, 2H), 6.93 - 7.12 (m, 3H), 7.51 (br. s, 2H). ESI [M+H]+:515.71. t-Butyl-4-(6-methoxy-2-(pyrrolidin-1-yl)-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin- 4-yl)piperazine-1-carboxylate (17e): 1H NMR (300 MHz, CDCl3) ^1.49 (s, 9H), 1.92 (br. s, 4H), 1.98 (br. s, 4H), 2.23 - 2.29 (m, 2H),2.81 - 2.94 (m, 8H), 3.30 (br. s, 2H), 3.60 (d, J= 4.90 Hz, 4H), 3.65 (br. s, 4H), 3.88 (s, 3H), 4.21 (t, J= 6.40 Hz, 2H), 6.96 (s, 1H), 7.12 (s, 1H). ESI [M+H]+:541.66. Example 4
Figure imgf000041_0001
General procedure for Boc-deprotection: To a solution of compound 17 (100 mg, 0.19 mmol) in 2mL dryDCM 0.5 mL TFA was added at 0˚C and the reaction mixture was stirred at room temperature for 2 hrs. The reaction mixture was quenched by adding 2 (N) NaOH solution, then the mixture was extracted with DCM and washed the organic part with brine, dried over sodium sulphate, concentrating the organic part gives compound 18. 4-(3-(6-Methoxy-4-(piperazin-1-yl)-2-(pyrrolidin-1-yl)quinazolin-7- yloxy)propyl)morpholine (18a): (150 mg, 0.27 mmol) of compound 17a was taken in 3 mL dry 1,4-dioxane. Then the reaction mixture was cooled to 0˚C and 1 ml 4N HCl was added. A pptwas formed which was filtered and the precipitate was the chloride salt of compound 18. 1H NMR (300 MHz, CD3OD) ^2.03 - 2.24 (m, 4H), 2.36 - 2.52 (m, 2H), 3.21 - 3.35 (m, 4H), 3.44 - 3.55 (m, 6H), 3.64 - 3.83 (m, 6H), 3.88 - 3.95 (m, 2H), 3.99 (s, 2H), 4.10 (br. s, 2H), 4.28 (br. s, 3H), 4.37 (t, J= 5.27 Hz, 2H), 7.28 (s, 1H), 7.40 (s, 1H). ESI [M+H]+:457.31 7-(3-(1H-Imidazol-1-yl)propoxy)-6-methoxy-4-(piperazin-1-yl)-2-(pyrrolidin-1- yl)quinazoline (18b): 1H NMR (600 MHz, CDCl3) δ 1.97 (t, J= 3.19 Hz, 4H), 2.12 - 2.15 (m, 1H), 2.33 (t, J= 6.13 Hz, 2H), 3.07 (d, J= 5.21 Hz, 2H), 3.57 - 3.59 (m, 4H), 3.62 - 3.65 (m, 4H), 3.87 - 3.90 (m, 2H), 3.91 (s, 3H), 4.07 (t, J= 5.87 Hz, 2H), 4.22 (t, J= 6.75 Hz, 2H), 6.93 - 6.94 (m, 1H), 6.97 (s, 1H), 7.00 (s, 1H), 7.04 (s, 1H), 7.49 (s, 1H). EI-HRMS [M]+: Calculated 437.2539. Found: 437.2539. 3-((6-Methoxy-4-(piperazin-1-yl)-2-(pyrrolidin-1-yl)quinazolin-7-yl)oxy)-N,N- dimethylpropan-1-amine (18c): 1H NMR (300 MHz, CDCl3) δ1.91-2.55 (m, 4H), 2.04 - 2.13 (m, 2H), 2.26 (s, 6H), 2.45 - 2.50 (m, 2H), 3.06 (d, J= 3.66 Hz, 4H), 3.56 (d, J= 4.03 Hz, 4H), 3.61 - 3.67 (m, 4H), 3.89 (s, 3H), 4.17 (t, J= 6.77 Hz, 2H), 6.99 (s, 1H), 7.01 (s, 1H). EI-HRMS [M]+: Calculated: 414.2743. Found: 414.2743. Example 5
Figure imgf000042_0001
4-(3-(6-Methoxy-4-(4-(phenylsulfonyl)piperazin-1-yl)-2-(pyrrolidin-1- yl)quinazolin-7-yloxy)propyl)morpholine (19): To a solution of compound 12 (50 mg, 0.12 mmol) in 2 mL dryDCM, DIPEA (0.1 mL, 0.24 mmol) and 1.5eqv of sulphonyl chloride were added keeping the reaction mixture in 0˚C. Then it was stirred at room temperature for 4 h. Reaction mixture was washed with water and extracted in DCM. Concentrating the organic part gives a mixture. Purification using chloroform- methanol (15%) gives the corresponding compounds as gummy solid.1H NMR (300 MHz, CDCl3) ^ 1.95(br. s, 4H), 2.05 (s, 2H), 2.45(d, J=3.96 Hz, 4 H), 2.51(s, 2H), 3.21 (br. s, 4H), 3.55 (br. s, 4H), 3.66 (br. s, 4H), 3.7 (br. s, 4H), 3.83 (s, 3H), 4.17 (s, 2H), 6.82 (s, 1H), 6.95 (s, 1H), 7.61 - 7.54 (m, 3H), 7.80 - 7.77 (m, 2H). EI-HRMS [M]+: Calculated: 596.2781 Found: 596.2785. 4-(4-Benzylpiperazin-1-yl)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)-2- (pyrrolidin-1-yl)quinazoline (20): Compound 20 was prepared by the same procedure as 13d. 1H NMR (300 MHz, CDCl3) δ 1.96 (t, J= 6.40 Hz, 4H), 2.06 (d, J= 6.78 Hz, 2H), 2.29 (s, 3H) 2.35 (d, J= 7.72 Hz, 4H), 2.56 - 2.50 (m, 6H), 2.66 - 2.61 (m, 4H), 3.65 - 3.57 (m, 10H), 3.87 (s, 3H), 4.17 (t, J= 6.69 Hz, 2H), 6.96 (s, 1H), 6.98 (s, 1H), 7.40 - 7.28 (m, 5H). EI-HRMS [M]+: Calculated: 559.3635. Found: 559.3641. 3-(4-(4-Benzylpiperazin-1-yl)-6-methoxy-2-(pyrrolidin-1-yl)quinazolin-7-yloxy)- N,N-dimethylpropan-1-amine (21a): Compound 21a was prepared by the same procedure as 13g. 1H NMR (600 MHz, CDCl3) δ 1.79 (t, J= 3.23 Hz, 4H), 2.15 - 2.09 (m, 2H), 2.55 (br. s, 4H), 2.67 - 2.62 (m, 6H), 3.20 (s, 6H), 3.58 (s, 2H),3.63 - 3.58 (m, 4H), 3.86 (s, 3H), 4.17 (t, J= 6.71 Hz, 2H), 6.96 (d, J= 11.15 Hz, 2H) ,7.28 - 7.25 (m, 1H), 7.37 - 7.31 (m, 4H). EI-HRMS [M]+: Calculated: 504.3213. Found: 504.3198. (4-(7-(3-(Dimethylamino)propoxy)-6-methoxy-2-(pyrrolidin-1-yl)quinazolin-4- yl)piperazin-1-yl)(phenyl)methanone (21b): Compound21b was prepared by the same procedure as 13c .1H NMR (300 MHz, CDCl3) δ 1.97 (d, J= 4.52 Hz, 4H), 2.14 - 2.05 (m, 2H), 2.30 (s, 6H), 2.54 (t, J= 7.25 Hz, 2H), 3.62 (d, J= 6.22 Hz, 8H), 3.87 (s, 3H), 4.04–3.88 (m, 4H), 4.16 (t, J= 6.50 Hz, 2H), 6.94 (s, 1H), 7.01 (s, 1H), 7.43 (s, 5H). ESI [M+H]+:519.61. Example 6
Figure imgf000044_0001
7-(Benzyloxy)-2-chloro-4-(4-cyclopentylpiperazin-1-yl)-6-methoxyquinazoline (22): 1-cyclopentyl Piperazine(507 mg, 0.003 mmol) was added to a stirred solution of 6 (1 g, 0.0029 mmol) in dry 1,4-Dioxaneand DIPEA (0.7 mL,0.005 mmol). The solution was stirred for 4 h at room temperature. After adding water a precipitate was formed which was filtered to give compound 7 (1.1g, 86% yield) as white solid (m.p-156-159 ˚C).1H NMR (300 MHz, CDCl3) ^ 1.39 - 1.50 (m, 2H), 1.58 (dd, J=7.72, 4.71 Hz, 2H), 1.68 - 1.75 (m, 2H), 1.88 (br. s, 2H), 2.51 - 2.60 (m, 1H), 2.64 - 2.70 (m, 4H), 3.66 - 3.71 (m, 1H), 3.76 - 3.82 (m, 4H), 3.96 (s, 3H), 5.25 (s, 2H), 7.06 (s, 1H), 7.18 (s, 1H), 7.31 - 7.41 (m, 3H), 7.42 - 7.48 (m, 2H).ESI [M+H]+:453.40. 2-Chloro-4-(4-cyclopentylpiperazin-1-yl)-6-methoxyquinazolin-7-ol (23):Pd(OH)2 (50 mg) was added to a solution of compound 22 (500 mg, 1.12 mol) and 1,4- cyclohexadiene (3mL, 2.21 mol) in20 mLEthanol. Reaction mixture was heated at 70˚C for 30min. The reaction mixture was filtered through celite and washed with methanol until the filtrate became colourless. The solution was concentrated to provide compound 23 (300 mg, 72% yield) as pale yellow solid (m.p-135˚C).1H NMR (300 MHz, CDCl3) ^1.43 - 1.61 (m, 4H), 1.66-1.74 (m, 2H), 1.88 (d, J= 7.54 Hz, 2H), 2.57 - 2.65 (m, 1H), 2.65-2.81 (m, 4H), 3.64-3.85(m, 4H), 3.95 (s, 3H), 7.01 (s, 1H), 7.17 (s, 1H). ESI [M+H]+:363.22. 2-Chloro-4-(4-cyclopentylpiperazin-1-yl)-6-methoxy-7-(3-(pyrrolidin- 1yl)propoxy)quinazoline (24): Compound 23 (200 mg, 0.55 mmol) and potassium carbonate (153 mg, 1.1 mmol) was taken in dryDMF (5mL). The reaction mixture was stirred at room temperature for 30 min. Then 1-(3-chloropropyl)pyrrolidine (121.8 mg, 0.0.825 mmol) was added and the mixture was stirred at 120˚C for 2 h. The reaction mixture was extracted with ethyl acetate and washed with 50 mL of water followed by brine wash, dried with sodium sulphate and concentrated. The residue was purified by flash column chromatography, eluting with 2% methanol in chloroform, to give compound 24 (170 mg, 79%) as a colourless gummy solid.1H NMR (300 MHz, CDCl3) ^ 1.37 - 1.51 (m, 2H), 1.52 - 1.64 (m, 2H), 1.66 - 1.76 (m, 2H), 1.83 (d, J=3.01 Hz, 4H), 1.88 (br. s, 2H), 2.10 - 2.22 (m, 2H), 2.50 - 2.59 (m, 1H), 2.60 - 2.71 (m, 8H), 2.71 - 2.76 (m, 2H), 3.77 (d, J= 4.52 Hz, 4H), 3.93 (s, 3H), 4.19 (t, J= 6.40 Hz, 2H), 7.04 (s, 1H), 7.14 (s, 1H). ESI [M+H]+:474.63. General procedure for the synthesis of compound 25: Compound 24 (80 mg, 0.17 mmol) and K2CO3 (93.9 mg, 0.68 mmol) were taken in dry 1,4-dioxane in a sealed tube followed by the addition of corresponding amines ( 1.1eqv.). Reaction mixture was heated at 120˚C for 24 h. 1,4-dioxane was removed under vacuum. The residue was extracted with chloroform and washed with 50 mL of water followed by brine wash, dried with sodium sulphate and concentrated and purified by flash column chromatography, eluting with Chloroform- CMA(Chloroform-methanol-5% NH3), to give corresponding derivatives. 4-(4-Cyclopentylpiperazin-1-yl)-6-methoxy-N-(4-methoxybenzyl)-7-(3-(pyrrolidin- 1-yl)propoxy)quinazolin-2-amine (25a):1H NMR (600 MHz, CDCl3) δ1.43 - 1.46 (m, 2H), 1.59 (d, J= 5.46 Hz, 2H), 1.74 (m, 2H), 1.86 (br. s, 4H), 1.90 (br. s., 2H), 2.16 - 2.20 (m, 2H), 2.55 (dt, J= 15.91, 7.94 Hz, 1H), 2.62 - 2.70 (m, 6H), 2.76 (t, J= 7.26 Hz, 2H), 2.81 - 2.85 (m, 1H), 3.03 (s, 1H), 3.71 (br. s, 4H),3.81 (s, 3H), 3.90 (s, 3H), 4.09 - 4.12 (m, 1H), 4.21 (t, J= 6.33 Hz, 2H), 4.61 (d, J= 4.89 Hz, 2H), 6.87 (d, J= 8.33 Hz, 2H), 6.97 (s, 1H), 7.00 (s, 1H), 7.32 (d, J= 8.21 Hz, 2H). ESI [M+H]+:575.68 4-(4-Cyclopentylpiperazin-1-yl)-N-(4-fluorobenzyl)-6-methoxy-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-2-amine (25b): 1H NMR (300 MHz, CDCl3) δ1.41 - 1.50 (m, 2H), 1.56 - 1.63 (m, 2H), 1.73 (d, J= 4.03 Hz, 2H), 1.76-1.86 (m, 4H), 1.89 (m, 2H), 2.13 - 2.19 (m, 2H),2.55 - 2.62 (m, 4H), 2.66 (d, J= 5.49 Hz, 4H), 2.68 - 2.72 (m, 2H), 3.50 (q, J= 6.95 Hz, 1H), 3.59-3.69 (m, 4H), 3.91 (s, 3H), 4.20 (t, J= 6.59 Hz, 2H), 4.65 (d, J= 5.12 Hz, 2H), 6.94 (s, 1H), 6.97 - 7.04 (m, 3H), 7.32 - 7.39 (m, 2H).ESI [M+H]+:563.46. 4-(4-Cyclopentylpiperazin-1-yl)-6-methoxy-N-(3-(4-methylpiperazin-1-yl)propyl)- 7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-2-amine (25c):1H NMR (300 MHz, CDCl3) δ1.43 - 1.51 (m, 2H), 1.57 - 1.62 (m, 2H), 1.70 - 1.75 (m, 2H), 1.81 (d, J= 4.03 Hz, 4H), 1.84 - 1.91 (m, 2H), 2.10 - 2.19 (m, 4H), 2.31 (s, 3H), 2.52 (dd, J= 13.72, 6.40 Hz, 12H), 2.63 - 2.72 (m, 8H), 3.41 (dd, J= 11.71, 5.85 Hz, 1H), 3.50 - 3.56 (m, 2H),3.59 - 3.66 (m, 4H), 3.90 (s, 3H), 4.19 (t, J= 6.77 Hz, 2H), 6.92 - 6.96 (m, 1H), 7.00 (s, 1H). ESI [M+H]+:595.52. N-(3-(1H-Imidazol-1-yl)propyl)-4-(4-cyclopentylpiperazin-1-yl)-6-methoxy-7-(3- (pyrrolidin-1-yl)propoxy)quinazolin-2-amine (25d):1H NMR (300 MHz, CDCl3) δ1.44 (d, J= 8.29 Hz, 2H), 1.60 (m, 2H), 1.73 (m, 2H), 1.83 (m, 4H), 1.91 (m, 2H), 2.07 - 2.18 (m, 4H), 2.30 (d, J= 6.03 Hz, 4H), 2.56 - 2.73 (m, 8H), 3.48 (d, J= 6.03 Hz, 3H), 3.66 (br. s, 4H), 3.85 - 3.94 (m, 3H), 4.09 (t, J= 6.78 Hz, 2H), 4.20 (t, J=6.59 Hz, 2H), 6.92 (s, 1H), 6.98 (d, J= 6.03 Hz, 2H), 7.06 (s, 1H), 7.53 (s, 1H). ESI [M+H]+:563.40. 4-(4-Cyclopentylpiperazin-1-yl)-6-methoxy-2-(4-methylpiperazin-1-yl)-7-(3- (pyrrolidin-1-yl)propoxy)quinazoline (25e): 1H NMR (300 MHz, CDCl3) δ 1.38 - 1.50 (m, 2H), 1.51 - 1.63 (m, 2H), 1.65-1.74 (m, 2H), 1.74-1.81 (m, 4H), 1.87-1.93 (m, 2H), 2.12 (dd,J= 14.18, 7.04 Hz, 2H), 2.22 - 2.30 (m, 2H), 2.33 (s, 3H), 2.48 (d, J= 4.57 Hz, 4H), 2.53 (br. s, 4H), 2.62 (d, J= 7.68 Hz, 2H), 2.66 (d, J=5.12 Hz, 4H), 2.85 - 2.91 (m, 1H), 3.45 (s, 1H), 3.60 (br. s, 3H), 3.85 (br. s, 2H), 3.87 (s, 3H), 4.16 (t, J= 6.59 Hz, 2H), 6.92 (s, 1H), 6.97 (s, 1H). ESI [M+H]+:538.62.
Example 7
Figure imgf000048_0001
t-Butyl-4-(2-(dimethylamino)-7-hydroxy-6-methoxyquinazolin-4-yl)piperazine-1- carboxylate (26): Compound26 was synthesized according to the procedure of compound 10 was synthesized as a yellow solid.1H NMR (300 MHz, CDCl3) δ 1.50 (s, 9H), 1.58-1.66 (m, 2H), 1.81-1.87 (m, 2H), 1.20-1.95 (m, 2H), 2.04-2.08 (m, 2H), 3.23 (s, 6H), 3.52-3.56 (m, 4H), 3.61-3.65 (m, 4H), 3.87 (s, 3H), 4.89-4.94 (m, 1H), 6.96 (s, 2H). ESI [M+H]+:472.37. 7-(Cyclopentyloxy)-6-methoxy-N,N-dimethyl-4-(piperazin-1-yl)quinazolin-2- amine(27): Compound27 was synthesized in the same way as compound 12 was synthesized.1H NMR (300 MHz, CDCl3) δ 1.62 - 1.67 (m, 2H), 1.81-1.86 (m, 2H),1.90 - 1.97 (m, 2H), 2.04 - 2.08 (m, 2H), 2.98 - 3.00 (m, 1H), 3.12 (t, J=9 Hz, 4H), 3.23 (s, 6H), 3.62 (t, J=9 Hz, 4H), 3.86 (s, 3H), 6.95 (s, 1H), 7.00 (s, 1H). ESI [M+H]+:372.35. 7-(Cyclopentyloxy)-6-methoxy-N,N-dimethyl-4-(4-methylpiperazin-1- yl)quinazolin-2-amine(28a): Compound28a was synthesized in the same way as compound 13a and 13b was synthesized.1H NMR (300 MHz, CDCl3) δ1.61-1.66 (m, 2H), 1.81-1.86 (m, 2H),1.90-1.97 (m, 2H),2.02-2.11 (m, 2H),2.37 (s, 3H),2.62 (t, J=9 Hz, 4H),3.23 (s, 6H),3.65 (t, J=9 Hz, 4H),3.87 (s, 3H),4.89-4.94 (m, 1H), 6.97 (s, 1H), 7.00 (s, 1H). ESI [M+H]+:386.43. 1-(4-(7-(Cyclopentyloxy)-2-(dimethylamino)-6-methoxyquinazolin-4-yl)piperazin- 1-yl)-2-methylpropan-1-one(28b):Compound28b was synthesized according to the procedure of compound 13a and 13b was synthesized.1H NMR (300 MHz, CDCl3) δ 1.15 (s, 3H),1.17 (s, 3H),1.61-1.66 (m, 2H),1.81-1.86 (m, 2H),1.90-2.01 (m, 2H),2.01- 2.08 (m, 2H),2.80-2.89 (m, 1H),3.22 (s, 6H),3.54-3.60 (m, 4H),3.73 (t,J=9 Hz, 2H),3.83 (t, J=9 Hz, 2H),3.87 (s, 3H),4.90-4.92 (m, 1H),6.93 (s, 1H), 6.95 (s, 1H). ESI [M+H]+:442.40. 4-(7-(Cyclopentyloxy)-2-(dimethylamino)-6-methoxyquinazolin-4-yl)-N,N- dimethylpiperazine-1-carboxamide(28c): Compound28c was synthesized in the same way as compound 13a and 13b was synthesized.1H NMR (300 MHz, CDCl3) δ 1.61- 1.65 (m, 2H), 1.80-1.87 (m, 2H),1.90-1.97 (m, 2H),2.03-2.07 (m, 2H),2.88 (s, 6H),3.21 (s, 6H),3.41-3.44 (m, 4H),3.55-3.59 (m, 4H),3.86 (s, 3H),4.88-4.93 (m, 1H),6.92 (s, 1H), 6.96 (s, 1H). ESI [M+H]+:443.36. Example 8
Figure imgf000050_0001
Figure imgf000050_0002
7-(Benzyloxy)-6-methoxy-N,N-dimethyl-4-(piperazin-1-yl)quinazolin-2- amine(29a): Compound29a was synthesized according to the procedure of compound 12.1H NMR (300 MHz, CDCl3) δ2.39 (s, 2H),3.13 (t,J=9 Hz, 2H),3.23 (s, 6H),3.63 (t, J=9 Hz, 4H),3.92 (s, 3H),5.25 (s, 2H),7.00 (s, 1H),7.08 (s, 1H),7.31- 7.43 (m, 3H), 7.50 (d, J=9 Hz, 2H). ESI [M+H]+:394.42. (4-(7-(Benzyloxy)-2-(dimethylamino)-6-methoxyquinazolin-4-yl)piperazin-1- yl)(phenyl)methanone(30a): Compound30a was synthesized in the same way as described for compound 13c and 13f.1H NMR (300 MHz, CDCl3) δ 3.23 (s, 6H),3.68 (br. s, 8H),3.91 (s, 3H),5.25 (s, 2H),6.99 (s, 1H),7.05 (s, 1H), 7.34-7.51 (m, 10H).ESI [M+H]+:498.35. 4-(7-(Benzyloxy)-2-(dimethylamino)-6-methoxyquinazolin-4-yl)-N,N- dimethylpiperazine-1-sulfonamide(30b): Compound30b was synthesized according to the procedure of compound 13a and 13b. 1H NMR (300 MHz, CDCl3) δ2.87 (s, 6H),3.21 (s, 6H), 3.44 (t,J=9 Hz, 4H),3.62 (t,J=9 Hz, 4H),3.90 (s, 3H),5.23 (s, 2H),6.95 (s, 1H),7.02 (s, 1H),7.32-7.41 (m, 3H), 7.46-7.49 (m, 2H).ESI [M+H]+:501.42. 7-(Benzyloxy)-6-methoxy-4-(piperazin-1-yl)-2-(pyrrolidin-1- yl)quinazoline(30c):Compound30c was synthesized in the same way as compound 12 was synthesized. 1H NMR (300 MHz, CDCl3) δ 1.85-1.88 (m, 2H), 3.17-3.19 (m, 2H),3.47 (t, J= 9 Hz, 3H),3.73-3.78 (m, 3H), 4.12 (s, 8H),5.10 (s, 2H),6.88 (s, 1H),7.00 (s, 1H),7.20-7.25 (m, 5H), 7.28-7.33 (m, 5H).ESI [M+H]+:524.47. (4-(7-(Benzyloxy)-6-methoxy-2-(pyrrolidin-1-yl)quinazolin-4-yl)piperazin-1- yl)(phenyl)methanone(31):Compound31 was synthesized in the same way as compound 13a and 13b was synthesized.1H NMR (300 MHz, CDCl3) δ 1.97 (t, J= 6 Hz, 4H),3.66 (t, J= 6.3 Hz, 12H),3.87 (s, 3H),6.88 (s, 1H), 7.31 (s, 1H), 7.45 (s, 5H). EI-HRMS[M]+: Calculated: 433.2114. Found: 433.2115. Example 9
Figure imgf000052_0001
t-Butyl-4-(7-(benzyloxy)-6-methoxy-2-((4-methoxybenzyl)amino)quinazolin-4- yl)piperazine-1-carboxylate(32a): Compound31a was synthesized in the same way as compound 14 was synthesized.1H NMR (300 MHz, CDCl3) δ 1.5 (s, 9H), 3.56 (d, J=6 Hz, 4H),3.61 (d,J=6 Hz, 4H),3.81 (s, 3H),3.93 (s, 3H),4.61 (d, J=6 Hz, 2H),5.25 (s, 2H),6.86 (s, 1H),6.89 (s, 1H),7.01 (s, 2H),7.30-7.33 (m, 2H),7.36-7.43 (m, 3H), 7.48- 7.51 (m, 2H).EI-HRMS [M]+: Calculated 585.2951. Found: 585.2945. t-Butyl-4-(7-(benzyloxy)-2-((2-hydroxy-2-methylpropyl)amino)-6- methoxyquinazolin-4-yl)piperazine-1-carboxylate(32b): Compound31b was synthesized according to the procedure of compound 14.1H NMR (300 MHz, CDCl3) δ1.26 (s, 6H), 1.47 (s, 9H),3.42 (d, J=6 Hz, 2H),3.53 (t,J= 9 Hz, 4H),3.62 (t, J= 9 Hz, 4H),3.87 (s, 3H),5.16 (s, 2H),6.95 (s, 1H),6.96 (s, 1H),7.30-7.39 (m, 3H), 7.43-7.46 (m, 2H).EI-HRMS [M]+: Calculated 537.2951. Found: 537.2950.
Example 10
Figure imgf000053_0001
7-(Benzyloxy)-6-methoxy-2-(4-methoxyphenethyl)-4-(piperazin-1- yl)quinazoline(33): Compound33 was synthesized in the same way as compound 12 was synthesized.1H NMR (300 MHz, CDCl3) δ 3.60 (t, J= 9 Hz, 4H), 3.70 (t, J= 9 Hz, 4H), 3.80 (s, 3H), 3.92 (s, 3H),4.60 (d, J= 6 Hz, 2H),5.24 (s, 2H),6.85 (s, 1H),6.88(s, 1H),7.02 (d, J= 6 Hz, 2H),7.29-7.43 (m, 5H), 7.49(d, J= 6 Hz, 2H). ESI [M+H]+:486.44. 7-(Benzyloxy)-6-methoxy-2-(4-methoxyphenethyl)-4-(4-methylpiperazin-1- yl)quinazoline(34a): Compound34a was synthesized in the same way as described for compound 13a and 13b.1H NMR (300 MHz, CDCl3) δ2.37 (s, 3H), 2.57 (t, J= 9 Hz, 4H), 3.76 (t, J= 9 Hz, 4H), 3.80 (s, 3H), 3.91 (s, 3H), 4.60 (d, J=6 Hz, 2H), 5.25 (s, 2H), 6.85 (s, 1H), 6.88 (s, 1H), 7.01-7.05 (m,2H),7.29-7.43 (m, 5H), 7.48-7.51 (m, 2H). EI- HRMS [M]+: Calculated 499.2583. Found: 499.2584. (4-(7-(Benzyloxy)-6-methoxy-2-(4-methoxyphenethyl)quinazolin-4-yl)piperazin-1- yl)(phenyl)methanone(34b): Compound33b was synthesized according to the procedure ofcompound 13c and 13f .1H NMR (300 MHz, CDCl3) δ 2.72 (br. s, 4H),3.51 (t, J=6 Hz, 2H), 3.80 (br. s, 3H), 3.89-3.94 (m, 5H), 4.61 (d, J= 6 Hz, 2H), 5.30 (s, 2H), 6.84 (s, 1H), 6.86 (s, 1H), 6.96 (s, 1H), 7.17 (s, 1H), 7.30 (s, 1H), 7.34- 7.40 (m, 3H), 7.44-7.49 ( m, 5H), 7.51-7.55 (m, 2H), 8.17-8.20 (m, 1H). ESI [M+H]+:509.38.
Figure imgf000054_0001
Table 1
Figure imgf000054_0002
Figure imgf000054_0003
Figure imgf000054_0004
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000056_0002
Figure imgf000057_0001
Figure imgf000057_0002
Figure imgf000058_0001
Example 11:
Experimental procedure for screening toll-like receptor 9 antagonistic activity To screen the synthesized small molecules based on quinazoline scaffolds for toll-like receptor 9 (TLR9) antagonisms, we designed a medium throughput biological assay based on toll-like receptor 9 activation in primary human immune cells. Among the immune cell subsets circulating in the peripheral blood, TLR9 has significant expression in plasmacytoid dendritic cells (PDCs) and B lymphocytes. Among these two cell subsets,plasmacytoid dendritic cells are capable of producing type I interferons (e.g. IFN-alpha) in response to TLR9 ligands. Type A and type B unmethylated cytosine-guanine rich DNA oligonucleotides (CpG oligonucleotides) are the bona fide ligands for TLR9. Example 12:
We established that IFN-alpha production from human peripheral blood mononuclear cells in response to type A CpG oligonucleotides (CpGA) almost exclusively results from TLR9 triggering on the PDCs (data not shown). Based on this principle we designed our screening assay where we isolated peripheral blood mononuclear cells (PBMCs) from venous blood collected from healthy donors using density gradient centrifugation. Then we cultured the PBMCs at 2-3*10^5 cells/200ul/well in a 96 well plate. We added the TLR9 agonist CpGA at 1uM in presence of escalating doses of the synthesized small molecules (0uM, 0.1uM, 1uM, 5uM, 10uM and 20uM). After overnight culture we collected the supernatants from the culture wells and looked for IFN-alpha using enzyme linked immunosorbent assay (ELISA). Molecules having TLR9 antagonistic activity inhibited IFN-alpha production in this screening assay. Example 13:
The structural evolution of the successively synthesized molecules was rationalized using the IFN-alpha inhibition data as depicted in the figures 1. A number of compounds with formula (I) were found to be efficient at antagonizing TLR9 activation at nanomolar concentration (Figures 1). Example 14:
Experimental Procedure for TLR9 antagonism in primary human pDC.
To screen the synthesized small molecules based on quinazoline scaffolds for toll-like receptor 9 antagonism, we designed a medium throughput biological assay based on toll-like receptor 9 activation in plasmacytoid dendritic cells (pDC), which were isolated from PBMCs of healthy donors. pDCs were isolated from PBMCs by magnetic immunoselection using anti-BDCA4 microbeads. The isolated pDCs were then cultured at 3*10^4 cells/100µl/well in a 96 well plate. We added the TLR9 agonist CpGA at 500nM in presence of escalating doses of the synthesized small molecules. After overnight culture we collected the supernatants from the culture wells and looked for IFN-alpha using enzyme linked immunosorbent assay (ELISA). Molecules having TLR9 antagonistic activity inhibited IFN-alpha production in this screening assay (Figure 2). Example 15:
Experimental Procedure for TLR9 Reporter assay
The synthesized small molecules based on quinazoline scaffolds were screened for TLR9 antagonism using a HEK-Blue-hTLR9 Secreted Alkaline Phosphatase (SEAP) reporter assay. Reporter HEK cell lines expressing human TLR9 along with a NF-κB promoter driven secreted embryonic alkaline phosphatase (SEAP) reporter gene were used. 70,000 cells per well were incubated overnight at 370C and 5% CO2 in a 96 well plate in complete DMEM medium supplemented with 100µg/ml Normocin. After incubation, the TLR9 agonist CpGB was added to the wells at a concentration of 1µM in presence of escalating doses of the synthesized small molecules and incubated at 370C and 5% CO2 for 24 hours. After incubation of the HEK cells, supernatants were collected and 20 ^l of supernatant was added to wells containing 200 ^l of Quanti-Blue Detection media. After 2 hours of further incubation, OD values were taken at 620nm in a spectrophotometer. Molecules having TLR9 antagonistic activity inhibited TLR9- mediated NF-kB activation in a dose-dependent manner (Figure 3).
Example 16:
Experimental procedure for screening for cytotoxicity of the identified TLR9 antagonists
MTT assay is a colorimetric assay for assessing cell viability. It is widely used for screening drugs and testing their cytotoxicity. NAD(P)H-dependent cellular oxidoreductase enzymes may, under defined conditions, reflect the number of viable cells present. These enzymes are capable of reducing the tetrazolium dye MTT 3-(4, 5dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide to its insoluble formazan, which has a purple colour. Viable cells with active metabolism convert MTT into a purple coloredformazan product with an absorbance maximum near 570 nm. When cells die, they lose the ability to convert MTT into formazan, thus colour formation serves as a useful and convenient marker of only the viable cells. The exact cellular mechanism of MTT reduction into formazan is not well understood, but likely involves reaction with NADH or similar reducing molecules that transfer electrons to MTT.
Example 17:
To check cytotoxicity of the synthesized TLR9 antagonists, HepG2 (a hepatic epithelial cell line) and SW480 (an intestinal mucosal epithelial cell line) cells were cultured in DMEM Complete media in 96 well plates at density of 30,000 cells per well, making a final volume of 100 µl/well. Treatment with different concentrations (0.1, 0.5,1, 10, 20 and 100 µM) of different candidate small molecule antagonists was added. Plates were incubated for 24 hours at 37deg C and 5% CO2 in incubator. After 24 hrs 50μl of MTT (5mg/ml) was added to each well and further incubated for 1 to 4 hours at 37°C. Then 100μl of DMSO was added to each well and properly mixed to ensure complete solubilisation of formazan crystals. Then absorbance was measured at 570 nm using an ELISA plate reader. None of the identified TLR9 antagonists showed considerable cytotoxicity at concentrations below 100µM on this assay (Figure 4). ADVANTAGES OF THE INVENTION
The main advantages of the present invention are:
The synthesized new compounds with general formula (I) of the present invention have several advantages.
1. The invention provides small molecules with general formula (I) which can effect immune stimulation via TLR9 antagonism.
2. The invention provides small molecules with general formula (I) which can inhibit immune stimulation via TLR9 antagonism.
3. The invention provides a medium throughput biological assays results involving human peripheral blood mononuclear cells, isolated human primary pDCs and reporter assay using transfected TLR9 cells to screen compounds with formula (I). All the three assays system was standardized and the results from all three assay systems can be correlated.
4. This invention provides compounds with formula (I) which can be used in a number of clinical contexts of autoreactive inflammation, including as pharmaceutical agents and methods for treating conditions involving unwanted immune activity in response to a suitable TLR ligand or TLR signalling agonist.

Claims

We Claim:
1. A compound of the general formula 1
Figure imgf000063_0001
wherein
X is independently selected from groups referred to as follows:
Figure imgf000063_0002
wherein R1 is independently selected from groups referred to as follows:
Figure imgf000063_0003
Figure imgf000064_0001
whereinR2 is a group having structure
where Y is optionally substituted or unsubstituted C0 to C3 alkyl; R5 and R6 are independently hydrogen or substituted or unsubstituted alkyl or R5 and R6 is joined to form substituted or unsubstituted heterocycle. wherein R2 is independentl selected from roups referred to as follows:
Figure imgf000064_0002
wherein R3 is independently selected from groups referred to as hydrogen, -OH and –OCH3 groups. 2. The compounds of general formula 1 as claimed in claim 1, wherein
represented compounds encompassing: 4-(4-(Isopropylsulfonyl)piperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(3- (pyrrolidin-1-yl)propoxy)quinazolin-2-amine13a(TBP-2-93);
4-(4-(Dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1yl)propoxy)quinazolin-4- yl)-N,N-dimethylpiperazin-1-sulfonamide13b(TBP-2-121);
Cyclopentyl(4-(2-(dimethylamino)-6-methoxy-7-(3-(pyrrolidin- 1yl)propoxy)quinazolin-4-yl)piperazine-1yl)methanone13c(TBP-2-117);
4-(4-(Cyclopentylmethyl)piperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(3- (pyrrolidin-1yl)propoxy)quinazolin-2-amine 13d(TBP-3-79);
4-(4-(Cyclopentylpiperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(3-(pyrrolidin- 1yl)propoxy)quinazolin-2-amine 13e(TBP-3-73);
(4-(2-(Dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline- 4-yl)piperazin-1-yl)(phenyl)methanone 13f(TBP-3-75);
4-(4-Benzylpiperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-2-amine 13g(TBP-3-67);
(4-(Aminomethyl)phenyl)(4-(2-(dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-4-yl)piperazin-1-yl)methanone 13h (TBP-3-113);
6-((4-(4-(2-(Dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-4-yl)piperazine-1-carbonyl)benzyl)amino)-6- oxohexanoic acid 13i (TBP-3-115);
6-((4-(4-(2-(Dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-4-yl)piperazine-1-carbonyl)benzyl)amino)-6- oxohexanoic acid 13i (TBP-3-115);
2-(4-(2-(dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin- 4-yl)piperazin-1-yl)-1-(4-fluorophenyl)ethanone13j (TBP-4-81);
t-Butyl-4-(6-methoxy-7-(3-morpholinpropoxy)-2-(pyrrolidin-1-yl)quinazoline- 4-yl)piperazine-1-carboxylate 17a(TBP-2-173);
t-Butyl-4-(6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)-2-(pyrrolidin-1- yl)quinazoline-4-yl)piperazine-1-carboxylate 17b(TBP-2-189); t-Butyl-4-(7-(3-(1H-imidazol-1-yl)propoxy)-6-methoxy-2-(pyrrolidin-1- yl)quinazolin-4-yl)piperazine-1-carboxylate 17c(TBP-2-191);
t-Butyl-4-(7-(3-(1H-imidazol-1-yl)propoxy)-6-methoxy-2-(pyrrolidin-1- yl)quinazoline-4-yl)piperazine-1-carboxylate 17d(TBP-3-47);
t-Butyl-4-(6-methoxy-2-(pyrrolidin-1-yl)-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-4-yl)piperazine-1-carboxylate 17e(TBP-2-145);
4-(3-(6-Methoxy-4-(piperazin-1-yl)-2-(pyrrolidin-1-yl)quinazolin-7- yloxy)propyl)morpholine 18a(TBP-2-179);
7-(3-(1H-Imidazol-1-yl)propoxy)-6-methoxy-4-(piperazin-1-yl)-2-(pyrrolidin- 1-yl)quinazoline 18b(TBP-3-69);
3-((6-Methoxy-4-(piperazin-1-yl)-2-(pyrrolidin-1-yl)quinazolin-7-yl)oxy)-N,N- dimethylpropan-1-amine 18c(TBP-3-49);
4-(3-(6-Methoxy-4-(4-(phenylsulfonyl)piperazin-1-yl)-2-(pyrrolidin-1- yl)quinazolin-7-yloxy)propyl)morpholine 19(TBP-2-185);
4-(4-Benzylpiperazin-1-yl)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)- 2-(pyrrolidin-1-yl)quinazoline 20(TBP-3-57);
3-(4-(4-Benzylpiperazin-1-yl)-6-methoxy-2-(pyrrolidin-1-yl)quinazolin-7- yloxy)-N,N-dimethylpropan-1-amine 21a(TBP-3-59);
(4-(7-(3-(Dimethylamino)propoxy)-6-methoxy-2-(pyrrolidin-1-yl)quinazolin-4- yl)piperazin-1-yl)(phenyl)methanone 21b(TBP-3-71);
4-(4-Cyclopentylpiperazin-1-yl)-6-methoxy-N-(4-methoxybenzyl)-7-(3- (pyrrolidin-1-yl)propoxy)quinazolin-2-amine 25a(TBP-3-91);
4-(4-Cyclopentylpiperazin-1-yl)-N-(4-fluorobenzyl)-6-methoxy-7-(3- (pyrrolidin-1-yl)propoxy)quinazolin-2-amine 25b(TBP-3-93);
4-(4-Cyclopentylpiperazin-1-yl)-6-methoxy-N-(3-(4-methylpiperazin-1- yl)propyl)-7-(3-(pyrrolidin-1-yl)propoxy)quinazolin-2-amine 25c(TBP-3-95); N-(3-(1H-Imidazol-1-yl)propyl)-4-(4-cyclopentylpiperazin-1-yl)-6-methoxy-7- (3-(pyrrolidin-1-yl)propoxy)quinazolin-2-amine 25d(TBP-3-97); 4-(4-Cyclopentylpiperazin-1-yl)-6-methoxy-2-(4-methylpiperazin-1-yl)-7-(3- (pyrrolidin-1-yl)propoxy)quinazoline 25e(TBP-3-99);
7-(Cyclopentyloxy)-6-methoxy-N,N-dimethyl-4-(piperazin-1-yl)quinazolin-2- amine 27 (TBP-3-149);
7-(Cyclopentyloxy)-6-methoxy-N,N-dimethyl-4-(4-methylpiperazin-1- yl)quinazolin-2-amine 28a (TBP-4-11);
1-(4-(7-(Cyclopentyloxy)-2-(dimethylamino)-6-methoxyquinazolin-4- yl)piperazin-1-yl)-2-methylpropan-1-one 28b (TBP-3-155);
4-(7-(Cyclopentyloxy)-2-(dimethylamino)-6-methoxyquinazolin-4-yl)-N,N- dimethylpiperazine-1-carboxamide 28c (TBP-3-157);
6-methoxy-N,N-dimethyl-4-(4-methylpiperazin-1-yl)-7-(piperidin-4- yloxy)quinazolin-2-amine28d (TBP-4-67);
6-methoxy-N,N-dimethyl-4-(4-methylpiperazin-1-yl)-7-((1-methylpiperidin-4- yl)oxy)quinazolin-2-amine28e (TBP-4-69);
6-methoxy-N,N-dimethyl-4-(4-methylpiperazin-1-yl)-7-((1-methylpyrrolidin-3- yl)oxy)quinazolin-2-amine 28f (TBP-4-71);
7-(4-(dimethylamino)phenoxy)-6-methoxy-N,N-dimethyl-4-(4- methylpiperazin-1-yl)quinazolin-2-amine 28g (TBP-4-73);
4-(4-cyclopentylpiperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(1- methylpiperidin-4-yloxy)quinazolin-2-amine 28h (TBP-4-77);
4-(4-cyclopentylpiperazin-1-yl)-6-methoxy-N,N-dimethyl-7-(1- methylpyrrolidin-3-yloxy)quinazolin-2-amine 28i (TBP-4-79);
7-(Benzyloxy)-6-methoxy-N,N-dimethyl-4-(piperazin-1-yl)quinazolin-2-amine 29a (TBP-2-159);
(4-(7-(Benzyloxy)-2-(dimethylamino)-6-methoxyquinazolin-4-yl)piperazin-1- yl)(phenyl)methanone 30a (TBP-3-135);
4-(7-(Benzyloxy)-2-(dimethylamino)-6-methoxyquinazolin-4-yl)-N,N- dimethylpiperazine-1-sulfonamide 30b (TBP-3-137); 7-(Benzyloxy)-6-methoxy-4-(piperazin-1-yl)-2-(pyrrolidin-1-yl)quinazoline 30c (TBP-2-149);
(4-(7-(Benzyloxy)-6-methoxy-2-(pyrrolidin-1-yl)quinazolin-4-yl)piperazin-1- yl)(phenyl)methanone31 (TBP-2-151);
t-Butyl-4-(7-(benzyloxy)-6-methoxy-2-((4-methoxybenzyl)amino)quinazolin-4- yl)piperazine-1-carboxylate 32a (TBP-3-121);
t-Butyl-4-(7-(benzyloxy)-2-((2-hydroxy-2-methylpropyl)amino)-6- methoxyquinazolin-4-yl)piperazine-1-carboxylate 32b (TBP-3-145);
7-(Benzyloxy)-6-methoxy-2-(4-methoxyphenethyl)-4-(piperazin-1- yl)quinazoline33(TBP-3-123);
7-(Benzyloxy)-6-methoxy-2-(4-methoxyphenethyl)-4-(4-methylpiperazin-1- yl)quinazoline 34a (TBP-3-127);
(4-(7-(Benzyloxy)-6-methoxy-2-(4-methoxyphenethyl)quinazolin-4- yl)piperazin-1-yl)(phenyl)methanone 34b (TBP-3-139).
tert-butyl 4-(2-(dimethylamino)-7-hydroxy-6-methoxyquinazolin-4- yl)piperazine-carboxylate 9 (TBP-2-71),
4-(4-cyclopentylpiperazin-1-yl)-2-(dimethylamino)-6-methoxyquinazolin-7-ol (TBP-4-75),
tert-butyl 4-(7-hydroxy-6-methoxy-2-(pyrrolidin-1-yl)quinazolin-4- yl)piperazine-1-carboxylate 15 (TBP-2-135)
(4-(7-hydroxy-6-methoxy-2-(pyrrolidin-1-yl)quinazolin-4-yl)piperazin-1- yl)(phenyl)methanone (TBP-2-151),
2-(dimethylamino)-6-methoxy-4-(4-methylpiperazin-1-yl)quinazolin-7-ol (TBP-4-9),
2-(dimethylamino)-6-methoxy-4-(piperazin-1-yl)quinazolin-7-ol (TBP-2-169), tert-butyl 4-(2-(dimethylamino)-6-methoxy-7-(3- morpholinopropoxy)quinazolin-4-yl)piperazine-1-carboxylate (TBP-2-165), tert-butyl 4-(2-(dimethylamino)-6-methoxy-7-(3-(pyrrolidin-1- yl)propoxy)quinazolin-4-yl)piperazine-1-carboxylate 11 (TBP-2-79).
3. The compounds of general formula 1 as claimed in claim 1, wherein The structural formulae of the re resentative com ounds are:
Figure imgf000069_0001
Figure imgf000069_0002
Figure imgf000070_0001
Figure imgf000070_0002
Figure imgf000071_0001
Figure imgf000072_0001
Figure imgf000072_0002
Figure imgf000073_0001
Figure imgf000074_0001
4.The process for the preparation of compounds of formula 1 as claimed in claim 1 comprising the steps of:
a. reacting compound of 6 with Boc-piperazxine to obtain compound 7;
b. reacting compound 7 obtained in step a) with amine to obtain compound of formula 8 or 14 or 32;
c. reacting compound 8 or 14 or 32 of step b) either with with hydrogen in presence of Pd/C to obtain compound of 9 or 15 or reacting with TFA to obtain 29a or 29b or 33 ; d. reacting compound 9 or 15 of step c) either with 1-chloro-3-bromopropane or bromocyclopentane to obtain compound 10 or 26 or 16 ;
e. reacting compound 10 or 16 of step d) with amine to compound 11 or 17;
f. reacting compound 11 or 17 of step e) or compound 26 of step d) or compound 14 of step b) with TFA to obtain 12 or 18 or 27;
g. reacting compound 12obtained in step f) or 29aor 29b of step c) with sulphonly chloride, alkly or aryl carboxylic acid or alkyl halide or aldehyde or reacting compound 33 of step c) with alkyl halide or benzoic acid to obtain the compound of formula 1.
5. The process as claimed in claim 4, further comprises reacting compound 27 of step f) with alkyl halide or acid chloride to obtain compound of formula 1 or compound 31.
6. The process as claimed in claim 5, wherein compound 31 further reacted with hydrogen in presence of Pd/C to obtain compound of formula 1.
7. The process as claimed in claim 4, further comprising(i) reacting compound 6 with N- cyclopentylpiperazine or N-methyl piperazine followed by dimethyl amine to obtain an interemediate
(ii) reacting the intermediate with hydrogen in presence of Pd/C to obtain compound 22 or 9b or 9c; and
(iii)reacting compound 22, 9b or 9c with 1-(3-chloropropyl)pyrrolidine or bromaamine or 4-hydroxy amine to obtain compound of formula 1.
8. The process as claimed in claim 4, wherein amine used in step b) r step e) is selected from the group consisting of,
Figure imgf000076_0001
9. The process as claimed in claim 4, wherein the sulphonyl chloride is selected from the group consisting of,
Figure imgf000076_0002
10. The process as claimed in claim 4, wherein the alkyl or aryl carboxylic acid or acid chloride is selected from the group consisting of,
Figure imgf000077_0001
11. The process as claimed in claim 4, wherein the alkyl halide is selected from the group consisting of,
Figure imgf000077_0002
.
12. The process as claimed in claim 4, wherein the alkyl o aryl aldehyde is selected from the group consisting of,
Figure imgf000077_0003
13. The compound as claimed in claim 1, wherein the compound is free form or in acceptable salt form.
14. The compound as claimed in claim 1, wherein the compound iscapable of inhibiting immune stimulation mediated through toll-like receptor 9 (TLR9) signalling.
15. A method of affecting toll-like receptor mediated signalling in response to a toll-like receptor ligand using compound of formula (I).
16. The method according claim 16, wherein the method involves detecting toll-like receptor 9 antagonism of effective amount of a compound of Formula (I) using a reporter cell line that reports nuclear factor kappa B expression downstream of toll-like receptor 9 (TLR9) signalling.
17. The compound of formula (I) as claimed in claim 1,wherein compound of formula I affect immune stimulation via interaction with a toll-like receptor 9 (TLR9).
18. The compound of formula (I) as claimed in claim 1,wherein the compound of formula I inhibit immune stimulation via toll-like receptor 9 (TLR9) antagonism.
19. A pharmaceutical composition comprising compound of formula 1.
20. The composition as claimed in claim 19,wherein the composition for use in treating conditions involving unwanted immune activity due to toll-like receptor 9 (TLR9) mediate signalling.
21. The compound as claimed in claim 1,wherein the compounds for use in treatingimmunodeficiency, inflammation, infection, sepsis, allergy, asthma, graft rejection, graft-versus host disease (GvHD) and cancer.
22. The compound as claimed in claim 1, wherein compound isforuseininhibiting an immune stimulatory nucleic acid associated response in a subject.
PCT/IN2017/050103 2016-03-21 2017-03-21 Blocking toll-like receptor 9 signaling with small molecule antagonist WO2017163264A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2017238758A AU2017238758B2 (en) 2016-03-21 2017-03-21 Blocking toll-like receptor 9 signaling with small molecule antagonist
CA3018537A CA3018537A1 (en) 2016-03-21 2017-03-21 Blocking toll-like receptor 9 signaling with small molecule antagonist
US16/086,926 US10662177B2 (en) 2016-03-21 2017-03-21 Blocking toll-like receptor 9 signaling with small molecule antagonist
EP17725784.7A EP3433249B1 (en) 2016-03-21 2017-03-21 Blocking toll-like receptor 9 signaling with small molecule antagonist
DK17725784.7T DK3433249T3 (en) 2016-03-21 2017-03-21 BLOCKING TOLL-LIKE RECEPTOR 9 SIGNALING WITH A SMALL MOLECULE ANTAGONIST

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201611009670 2016-03-21
IN201611009670 2016-03-21

Publications (2)

Publication Number Publication Date
WO2017163264A1 true WO2017163264A1 (en) 2017-09-28
WO2017163264A4 WO2017163264A4 (en) 2017-11-30

Family

ID=58772612

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2017/050103 WO2017163264A1 (en) 2016-03-21 2017-03-21 Blocking toll-like receptor 9 signaling with small molecule antagonist

Country Status (6)

Country Link
US (1) US10662177B2 (en)
EP (1) EP3433249B1 (en)
AU (1) AU2017238758B2 (en)
CA (1) CA3018537A1 (en)
DK (1) DK3433249T3 (en)
WO (1) WO2017163264A1 (en)

Cited By (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019092739A1 (en) * 2017-11-08 2019-05-16 Council Of Scientific & Industrial Research Purine based compounds as toll-like receptor 9 antagonist
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
WO2019193533A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2'-cyclic dinucleotides
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
WO2019193542A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides
WO2019200247A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020214663A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214652A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020254473A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Quinazoline prodrugs for the treatment of viral infections and further diseases
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2024040109A3 (en) * 2022-08-16 2024-04-18 Bristol-Myers Squibb Company Kras inhibitors

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000281660A (en) * 1999-03-29 2000-10-10 Sumitomo Pharmaceut Co Ltd Quinazoline derivative
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
US6221882B1 (en) 1997-07-03 2001-04-24 University Of Iowa Research Foundation Methods for inhibiting immunostimulatory DNA associated responses
US6479504B1 (en) 1999-06-16 2002-11-12 The University Of Iowa Research Foundation Antagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases
WO2003103586A2 (en) 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
WO2005007672A2 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists
WO2008030455A2 (en) 2006-09-05 2008-03-13 Coley Pharmaceutical Group, Inc. Small molecule inhibitors of toll-like receptor 9
US20090099165A1 (en) * 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2010036908A1 (en) 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Use of benzoxazole compounds in the treatment of malaria

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2239227C (en) * 1996-10-01 2007-10-30 Kenji Matsuno Nitrogen-containing heterocyclic compounds
WO2007114323A1 (en) * 2006-04-04 2007-10-11 Taisho Pharmaceutical Co., Ltd. Aminopyrrolidine compound

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221882B1 (en) 1997-07-03 2001-04-24 University Of Iowa Research Foundation Methods for inhibiting immunostimulatory DNA associated responses
JP2000281660A (en) * 1999-03-29 2000-10-10 Sumitomo Pharmaceut Co Ltd Quinazoline derivative
US6479504B1 (en) 1999-06-16 2002-11-12 The University Of Iowa Research Foundation Antagonism of immunostimulatory CpG-oligonucleotides by 4-aminoquinolines and other weak bases
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
WO2003103586A2 (en) 2002-06-05 2003-12-18 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
WO2005007672A2 (en) * 2003-06-20 2005-01-27 Coley Pharmaceutical Gmbh Small molecule toll-like receptor (tlr) antagonists
US7410975B2 (en) 2003-06-20 2008-08-12 Coley Pharmaceutical Group, Inc. Small molecule toll-like receptor (TLR) antagonists
US20090099165A1 (en) * 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
WO2008030455A2 (en) 2006-09-05 2008-03-13 Coley Pharmaceutical Group, Inc. Small molecule inhibitors of toll-like receptor 9
WO2010036908A1 (en) 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Use of benzoxazole compounds in the treatment of malaria

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
AKIRA, S ET AL., ANNU REV IMMUNOL, vol. 21, 2003, pages 335 - 376
AKIRA, S ET AL., ANNU REV IMMUNOL., vol. 21, 2003, pages 335 - 376
ALEXOPOULOU, L ET AL., NATURE, vol. 413, no. 6857, 2001, pages 732 - 738
BAMBOAT, Z. M ET AL., HEPATOLOGY, vol. 51, no. 2, 2010, pages 621 - 632
BARRAT, F. J ET AL., EUR J IMMUNOL., vol. 37, no. 12, 2007, pages 3582 - 3586
BARTON, G. M ET AL., NAT IMMUNOL., vol. 7, no. L, 2006, pages 49 - 56
CALCATERRA, C ET AL., J IMMUNOL., vol. 181, no. 9, 2008, pages 6132 - 6139
CHRISTENSEN, S. R ET AL., J EXP MED, vol. 202, no. 2, 2005, pages 321 - 331
GANGULY D ET AL., J EXP MED, 2009
GANGULY, D. ET AL., J EXP MED., vol. 206, no. 9, 2009, pages 1983 - 1994
GANGULY, D. ET AL., NAT REV IMMUNOL., vol. 13, no. 8, 2013, pages 566 - 577
HEIL, F ET AL., SCIENCE, vol. 303, no. 5663, 2004, pages 1526 - 1529
HEMMI, H ET AL., NATURE, vol. 408, no. 6813, 2001, pages 740 - 745
HOQUE, R ET AL., GASTROENTEROLOGY, vol. 141, no. 1, 2011, pages 358 - 369
ITAGAKI, K ET AL., SHOCK, vol. 36, no. 6, 2011, pages 548 - 552
LANDE R ET AL., NATURE, 2007
LANDE, R ET AL., NATURE, vol. 449, no. 7162, 2007, pages 564 - 569
LANDE, R ET AL., NATURE, vol. 449, no. 7162, 2011, pages 564 - 569
LEADBETTER, F. A ET AL., NATURE, vol. 416, no. 6881, 2002, pages 603 - 607
LUND, J. M ET AL., PROCNATLACADSCI U S A., vol. 101, no. 15, 2004, pages 5598 - 5603
MARSHAK-ROTHSTEIN, A, NAT REV IMMUNOL., vol. 6, no. 11, 2006, pages 823 - 835
MEDZHITOV, R;NAT. REV. IMMUNOL., vol. 1, 2001, pages 135 - 145
WALLACE, D., J;LUPUS, vol. 5, no. 1, 1996, pages 59 - 64

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10662416B2 (en) 2016-10-14 2020-05-26 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome
US11274285B2 (en) 2016-10-14 2022-03-15 Precision Biosciences, Inc. Engineered meganucleases specific for recognition sequences in the Hepatitis B virus genome
AU2018364807B2 (en) * 2017-11-08 2022-05-19 Council Of Scientific & Industrial Research Purine based compounds as toll-like receptor 9 antagonist
WO2019092739A1 (en) * 2017-11-08 2019-05-16 Council Of Scientific & Industrial Research Purine based compounds as toll-like receptor 9 antagonist
US11168084B2 (en) 2017-11-08 2021-11-09 Council Of Scientific & Industrial Research Purine based compounds as toll-like receptor 9 antagonist
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
US10966999B2 (en) 2017-12-20 2021-04-06 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
US11292812B2 (en) 2018-04-06 2022-04-05 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotides
WO2019193543A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides
WO2019193542A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides
WO2019193533A1 (en) 2018-04-06 2019-10-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'2'-cyclic dinucleotides
US11149052B2 (en) 2018-04-06 2021-10-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′-cyclic dinucleotides
WO2019200247A1 (en) 2018-04-12 2019-10-17 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
US11142750B2 (en) 2018-04-12 2021-10-12 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
US11788077B2 (en) 2018-04-12 2023-10-17 Precision Biosciences, Inc. Polynucleotides encoding optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
WO2019211799A1 (en) 2018-05-03 2019-11-07 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
WO2020092528A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
EP4371987A1 (en) 2018-10-31 2024-05-22 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
WO2020092621A1 (en) 2018-10-31 2020-05-07 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
US11766447B2 (en) 2019-03-07 2023-09-26 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178769A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
WO2020178768A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
WO2020178770A1 (en) 2019-03-07 2020-09-10 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP4458416A2 (en) 2019-04-17 2024-11-06 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214652A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020214663A1 (en) 2019-04-17 2020-10-22 Gilead Sciences, Inc. Solid forms of a toll-like receptor modulator
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
WO2020254473A1 (en) * 2019-06-18 2020-12-24 Janssen Sciences Ireland Unlimited Company Quinazoline prodrugs for the treatment of viral infections and further diseases
CN114008029A (en) * 2019-06-18 2022-02-01 爱尔兰詹森科学公司 Quinazoline prodrugs for the treatment of viral infections and additional diseases
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
WO2021067181A1 (en) 2019-09-30 2021-04-08 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
EP4458975A2 (en) 2019-09-30 2024-11-06 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
WO2021113765A1 (en) 2019-12-06 2021-06-10 Precision Biosciences, Inc. Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome
WO2021188959A1 (en) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2022241134A1 (en) 2021-05-13 2022-11-17 Gilead Sciences, Inc. COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS
WO2022271677A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271650A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271659A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2022271684A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
WO2024040109A3 (en) * 2022-08-16 2024-04-18 Bristol-Myers Squibb Company Kras inhibitors

Also Published As

Publication number Publication date
EP3433249B1 (en) 2022-11-09
US20190092758A1 (en) 2019-03-28
DK3433249T3 (en) 2023-02-13
WO2017163264A4 (en) 2017-11-30
CA3018537A1 (en) 2017-09-28
AU2017238758A1 (en) 2018-10-11
US10662177B2 (en) 2020-05-26
AU2017238758B2 (en) 2021-01-21
EP3433249A1 (en) 2019-01-30

Similar Documents

Publication Publication Date Title
AU2017238758B2 (en) Blocking toll-like receptor 9 signaling with small molecule antagonist
CN109311851B (en) Dihydro pyrimidinyl benzazepine carboxamide compounds
EP2218720B1 (en) 2-2'-Bis-thiazole derivatives as antiviral agents
WO2005107760A1 (en) Compounds and compositions as inducers of keratinocyte differentiation
CN1500089A (en) Fused pyridine derivatives as capsaicin receptor antagonists for the treatment of pain
AU2018379499B2 (en) Novel pyrimidine derivative having effect of inhibiting cancer cell growth and pharmaceutical composition containing same
CN109563144B (en) Compound (I)
CA2832504A1 (en) Compounds for inhibiting cell proliferation in egfr-driven cancers
ES2418479T3 (en) Antagonists of the hedgehog route of disubstituted phthalazines
JP2010522186A (en) Compound
CN110590809A (en) Macrocyclic deaza-purinones for the treatment of viral infections
WO2020172932A1 (en) Aniline wdr5 protein-protein interaction inhibitor, preparation method therefor and use thereof
CN106967004A (en) IDO1 and IDO2 double inhibitors, its preparation method and its medical usage containing urea groups
CN109810098B (en) A dual-target inhibitor of PARP-1 and PI3K containing phthalazine-1(2H)-one structure
GB1603228A (en) Indole derivatives a process for preparing them and pharmaceutical compositions containing them
CN101967127A (en) Quinazoline derivative and preparation method thereof and application of quinazoline derivative for preparing anticancer drugs
EP3707140B1 (en) Purine based compounds as toll-like receptor 9 antagonists
EP3388430A1 (en) Compound, compound for use in the treatment of a pathological condition, a pharmaceutical composition and a method for preparing said compound
KR20210143131A (en) 2-Aminoquinazoline derivatives and antiviral composition comrising the same
CN113880814B (en) Pyrimidine amine compound and application thereof
CN106565684A (en) 6-pyrromonazole substituted quinazoline compound, and derivative, synthetic method and application thereof
WO2021154661A1 (en) 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
US20230140430A1 (en) 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
WO2021154665A1 (en) 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
KR20230091052A (en) Novel compounds for the degradaton of targeted proteins or polypeptides by polyubiquitination

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 3018537

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017238758

Country of ref document: AU

Date of ref document: 20170321

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2017725784

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017725784

Country of ref document: EP

Effective date: 20181022

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17725784

Country of ref document: EP

Kind code of ref document: A1